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GLUTAMATE AS A NEUROTRANSMITTER
The excitatory action of glutamate in the mammalian brain and spinal cord 
has been known since the 1950s. The idea, however that glutamate functions 
as a neurotransmitter was introduced in the 1960s (Curtis and Watkins, 1960; 
Crawford and Curtis, 1964). In the late 1970s, it became widely recognized as 
the primary excitatory neurotransmitter within the vertebrate nervous system 
(CNS). 
Glutamate is largely derived from intermediary glucose metabolism and 
also can be formed directly from glial cell synthesized glutamine stores. The 
synaptic transmission and synaptic cleft levels of glutamate are regulated by 
variety of transporters which are the primary means for synaptic inactivation 
of glutamate (Maragakis and Rothstein, 2001). Besides its essential function in 
energy metabolism, glutamate plays major roles in many important psychological 
processes such as synaptic transmission, plasticity and neurotoxicity. Virtually 
all brain cells have receptors that allow them to respond to glutamate and over 
half of the brain’s 100 billion neurons generate it as neurotransmitter. In contrast, 
the brain has only about 10000 dopamine-generating neurons (McGeer et al., 
1987). Therefore, glutamate is involved in nearly all aspects of brain function 
including cognition, memory and learning. Consequently, abnormal changes 
in glutamatergic neurotransmission, in particular excessive glutamate release, 
can lead to a neuronal dysfunction resulting in a variety of neurological and 
psychiatric disorders. These include epilepsy, amnesia, motor neuron disease, 
stroke, traumatic brain injury, pain, anxiety and schizophrenia. Therefore, 
there has been a great deal of interest in developing therapeutic strategies that 
can influence the function of glutamate receptors. However, because of the 
ubiquitous nature of the glutamate synapse, drugs that interfere with glutamate 
receptor function were expected to impact glutamatergic function throughout the 
central nervous system, resulting in an overt disruption in basic brain function.
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 The discovery of a distinct class of glutamate receptors, called metabotropic 
glutamate (mGlu) receptors, however, has changed the classical view of glutamate 
receptors and has brought forth the opportunity of developing drugs that modify 
glutamate neurotransmission in a functionally selective manner (Conn and Pin, 
1997; Schoepp, 2001; Schoepp and Conn, 2002).
Figure 1. Hypothetical synapse illustrating the general synaptic localization and function of 
glutamatergic receptors. The ionotropic glutamate receptors, N-methyl-D-aspartate (NMDA), 
kainate and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtypes, largely 
function to mediate fast receptor transmission, but also mediate the use dependent changes required 
for neuronal plasticity. The vesicular transporters (vGluT1 and vGluT2) load glutamate into 
vesicles presynaptically. The glial, astrocyte and postsynaptic glutamate transporters (excitatory 
amino-acid transporters, EAAT1–5) are thought to mediate the uptake of glutamate and therefore 
termination of synaptic transmission. The metabotropic glutamate receptors have a diverse synaptic 
localization and function pre- and postsynaptically to modulate neurotransmitter release and 
postsynaptic excitability, respectively. For instance, the group II mGlu (mGlu2/3) receptor agonists 
probably serve to stimulate mGlu autoreceptors on glutamatergic terminals to suppress excitatory 
neurotransmission at selected synapses in the central nervous system. By contrast, mGlu5 receptor 
antagonists might inhibit mGlu5-mediated potentiation of NMDA receptor ion currents and 
potentially disrupt the formation of memory processes associated with stressful events (modified 




Before the discovery of mGlu receptors, it was thought that glutamate exerts 
its physiological action through receptors that act directly as ion channels. These 
ionotropic (iGlu) receptors were classified into three broad subtypes according 
to their preferential agonists as the N-methyl-d-aspartate (NMDA), α-amino-5-
hydroxy-3-methyl-4-isoxazole-propionic-acid (AMPA), and kainate receptors 
(Hollmann and Heinemann, 1994; Huntley et al., 1994). Binding of glutamate to 
these subclasses of receptors stimulates Ca2+ and Na+ entry into neurons through 
channels formed either by the receptor itself (as is the case with the NMDA 
receptor subtype) or by opening voltage-sensitive ion channels that are on the 
cell membrane. The ionotropic glutamate receptors are expressed by nearly all 
subtypes of neurons and mediate fast excitatory neurotransmission throughout 
the brain with maximum densities in the cerebral cortex, hippocampus, striatum, 
septum and amygdala (Monaghan et al., 1989; Young and Fagg, 1990). Thus, 
direct pharmacological manipulation of this group of receptors may produce a 
global disruption in brain function and produce profound side effects ranging 
from disruption of movement to impairment of attention and memory.
In the late 1980s it became apparent that the glutamate-mediated 
neurotransmission is more complex since glutamate was reported to stimulate 
phospholipase C (PLC) via a receptor that did not belong to the iGlu receptor 
families (Sladeczek et al., 1985; Nicoletti et al., 1986; Sugiyama et al., 1987). 
These results strongly suggested that glutamate, like GABA, serotonin and 
acetylcholine, not only activated fast-acting ionotropic receptors but also second 
messenger systems through coupling with G-proteins. Thanks to the molecular 
methodologies, our knowledge on this new glutamate receptor family, now called 
metabotropic glutamate (mGlu) receptors is expanding rapidly.
At least eight mGlu receptor subgroups have been identified and are 
subdivided in three groups based on their primary structure, second messenger 
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coupling and pharmacology: group I (mGlu1 and 5), group II (mGlu2 and 3) 
and group III (mGlu4, 6, 7 and 8). The group I receptors are positively linked 
to phospoholipase C whereas the group II and III receptors are negatively 
coupled to adenylyl cyclase, in that upon activation they inhibit forskolin-
stimulated cyclic AMP formation (Table 1). Several characteristics of mGlu 
receptors that distinguish them from iGlu receptors also make them important 
pharmacotherapeutic targets (Figure 1). First, unlike the iGlu receptors that 
mediate fast synaptic neurotransmission, activation of mGlu receptors modulates 
neuronal activity in a manner similar to neuromodulators such as dopamine and 
serotonin, which have been effective targets of psychoactive drugs for treatment 
of most psychiatric disorders (Conn and Pin, 1997; Schoepp, 2001). Second, the 
distribution and function of these receptors is highly diverse and heterogeneous. 
Different subclasses of mGlu receptors are localized differently at both regional 
and cellular levels. For example, mGlu2 and 3 are found in high density in the 
cerebral cortex and limbic regions (Phillips et al., 2000; Tamaru et al., 2001), 
whereas the mGlu6 receptor is found almost exclusively in the retina (Vardi et 
al., 2000). In addition, different classes of mGlu receptors are found on different 
neuronal and non-neuronal elements such as postsynaptic or presynaptic 
membranes or glial cells. Within the synapse, the group I receptors are typically 
localised postsynaptically in somatodendritic domains, while group II and 
III receptors are predominantly presynaptic, localised in axonal domains and 
axon terminals. Only the mGlu7 receptors are situated in the active zone of the 
presynaptic terminal, while the other receptor subtypes, in particular mGlu2 and 
3, are located far from the site of release. Thus, unlike ligands, that target the iGlu 
receptors and produce non-discriminate excitation or inhibition of fast synaptic 
neurotransmission throughout the nervous system, heterogeneous distribution 
of various subtypes of mGlu receptors with distinct functional and anatomical 




Table 1. Classification of the metabotropic glutamate (mGlu) receptors.






Most often postsynaptic at glutamatergic synapses. 
Indicated in synaptic plasticity, including long-term 
potentiation/depression (LTP/LTD). Cerebellar 
localization in granular cell and parallel fibre layers 
Agonists: DHPG,  quisqualate, 
1S,3R-ACPD
Antagonist: LY393675 





Most often postsynaptic at glutamatergic synapses, 
also found in glial cells. High expression in several 
forebrain region including hippocampus and 
amygdale. Indicated in synaptic plasticity, especially 
some forms of cortical and hippocampal LTD. 
Agonists: DHPG, quisqualate, 
1S,3R-ACPD, CHPG 






Localization largely presynaptic on glutamatergic and 
other neurotransmitter synapses. High expression in 
forebrain regions including hippocampus and 
amygdale; also in certain layers of the cortex and the 
cerebellum. Linked to hippocampal LTD and 





Potentiator: LY487379,  





Widely expressed in glial cells but also discrete 
localization both pre- and postsynaptic on 
glutamatergic and other neurotransmitter synapses. 
Expression within forebrain regions including 
hippocampus and thalamus. Linked to neurotropin 










Localization both pre- and postsynaptic on 
glutamatergic and other neurotransmitter synapses. 
Linked to cerebellar plasticity and motor learning 
Agonists: L-SOP, ACPT-1, 
 L-AP4 






Expression confirmed only in retinal bipolar ON cells. 
Knockout animals reported to have visual acute 
deficit  






Localization both pre- and postsynaptic on 
glutamatergic and other neurotransmitter synapses in 
limbic and cortical regions. Has lower affinity for 
glutamate than other subtypes and only presynaptic 
localization in the active zone of the synapses. 
Thought to serve a classical autoreceptor function. 
Agonists: L-SOP,  L-AP4 
Antagonists: MSOP, MAP4, 
LY341495 (100fold lower 





Localization largely presynaptic on glutamatergic and 
other neurotransmitter synapses. High expression in 
forebrain regions including hippocampus and 
amygdale. Linked to regulation of lateral perforant 
path





GROUP II METABOTROPIC GLUTAMATE RECEPTORS (MGLU2/3)
Among the members of the mGlu receptor family, the most is known about 
the group II receptors (mGlu2/3). Converging results from in situ hybridization 
(Ohishi et al., 1993a-b) and immunochemical studies (Ohishi et al., 1998; 
Petralia et al., 1996) using non-selective group II mGlu receptor antibodies  have 
suggested that mGlu2 and 3 receptors are localized widely throughout circuits of 
relevance for neuropsychiatric and neurological disorders, such as the neocortex, 
thalamus, striatum, amygdala and hippocampus. Electron microscopy studies 
have shown that both neuronal and glial processes display mGlu2/3 receptor 
immunreactivity (Liu et al., 1998; Shigemoto et al., 1997; Petralia et al., 1996). 
It is clear, however, that mGlu3 but not mGlu2 receptor is expressed in glial cells 
(Ohishi et al., 1993; Mineff and Valtschanoff, 1999).  Although the role of these 
glial receptors is yet undetermined, given the major contribution of glia to the 
uptake and the synthesis of glutamate, activation of these mGlu3 receptors is 
likely to result in significant functional effects (Winder and Conn, 1996).  
In contrast, much more is understood about the function of mGlu2/3 receptors 
expressed in the neurons. In general, mGlu2/3 receptors have a predominant 
localization at the periphery of the synaptic area, where they function to monitor 
glutamate that has escaped from the synaptic space. The presynaptic localization 
of mGlu2/3 receptors in comparison with the localization of mGlu7 receptors at 
the active zone of the synapse explains the vast differences in the affinities of 
these receptors for their endogenous ligand. Glutamate is highly potent at group 
II receptors (generally in the range of 0.3-20 µM), but the EC
50
 value of glutamate 
at mGlu7 receptors is >500µM. Due to this comparatively high potency of 
glutamate, mGlu2/3 receptors can be activated by relatively low concentrations 
of glutamate. Importantly, endogenously released glutamate can activate group 
II mGlu receptors in a use-dependent manner. Under normal conditions when 
glutamate is generally confined to the active zone of the synaptic space, activation 
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of mGlu2/3 receptors is not detected. Under conditions of glutamate spillover 
from the synapses, for instance due to high-frequency stimulation or glutamate 
uptake blockade, mGlu2/3 receptors become activated leading to suppression in 
glutamate release (Scanziani et al., 1997; Chen et al., 2001; Kew et al., 2001; 
Huang et al., 1997). This inhibitory action on glutamatergic neurotransmission 
is mediated via the inhibition of voltage-gated calcium channels (VGCCs), 
activation of potassium (K+) and/or inhibition of the exocytotic process 
downstream from calcium entry (Conn and Pin, 1997; Schoepp, 2001; Anwyl, 
1999). These data suggest that mGlu2/3 receptors may provide a negative 
feedback to keep glutamate transmission within the physiological range and thus 
prevent hyperexcitability from interfering with normal brain function.
The discovery of novel subtype-selective ligands was crucial to determine the 
role of mGlu2/3 receptors in neuronal function. The first potent and selective 
group II receptor agonist described was LY354740 and its more potent derivative 
LY379268, both active in the nanomolar range (Schoepp et al., 1997; Monn 
et al., 1999). More recently, MGS 0008 and MGS 0028, also derivates of 
LY354740, have been developed with higher potencies (Nakazato et al., 2000). 
Unfortunately, most of the group II ligands are equipotent at mGlu2 and mGlu3 
receptors, indicating that the pharmacology of these receptors is very similar. 
 Despite their low brain penetration, these molecules have been successfully 
used to analyze the psychological role of mGlu2/3 receptors in vitro and in 
vivo (Anwyl, 1999). For example, both LY354740 and LY379268 suppressed 
electrically-evoked and 5HT
2A
 receptor mediated glutamatergic excitation in rat 
prefrontal cortex (Marek et al., 2000), whereas per se they had no effect on basal 
extracellular level of glutamate (Battaglia et al., 1997; Moghaddam and Adams, 
1998; Lorrain et al., 2003a). Moreover, LY354740 and LY379268 have been 
shown to be active in animal models of anxiety, global ischemia and psychosis, at 




Taken together, the unique pharmacology of mGlu2/3 receptors, their forebrain 
localization in key limbic-related cortical/thalamic/striatal/amygdaloid circuits, 
and the promise of subtle modulation of glutamatergic neurotransmission make 
these receptors intriguing targets for a wide variety of neuropsychiatric disorders 
associated with excessive or inappropriate glutamate release.
SCHIZOPHRENIA
Schizophrenia is a debilitating psychiatric disorder that effect 1% of the 
world‘s population and is more prevalent than Alzheimer’s disease or multiple 
sclerosis. The disorder is characterized by a combination of negative (motor 
impairment, emotional lability, blunted affect and social withdrawal) and 
positive symptoms (paranoia, hallucination, delusion and violent behaviour) as 
well as marked cognitive deficits. While the etiology of schizophrenia is currently 
unknown, the disease appears to arise from a complex interaction of biological, 
environmental and genetic factors. 
Until recently, the dominant hypothesis for the pathophysiology underlying 
schizophrenia has stated that excessive dopaminergic transmission in the 
forebrain is a key causative factor. This dopamine hyperfunction hypothesis 
is based primarily on the observation that all clinically effective antipsychotic 
drugs, such as haloperidol or chlorpromazine, have substantial antagonist 
activity at dopamine D
2
 receptors (Seeman and Lee, 1975; Seeman, 1987). 
Secondly, abuse of stimulants like the indirect dopamine agonist amphetamine 
and cocaine can induce psychosis that resembles the positive symptoms of 
schizophrenia (Angrist, 1994). These findings have placed the D
2
 dopamine 
receptor at the forefront of antipsychotic drug development. However, there are 
several recognized shortcomings of D
2
 antagonist therapy. Typical and atypical 
antipsychotics, which act at least in part by blocking D
2
 dopamine receptors, are 
effective in treating the positive symptoms of schizophrenia but residual negative 
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symptoms often remain, and at least one quarter of schizophrenic patients do not 
respond to dopamine antagonist therapy (Hellewell, 1999). Furthermore, current 
antipsychotics induce a variety of severe side effects including Parkinson’s 
disease-like symptoms, tardive dyskinesia, sedation and sexual dysfunction 
(Casey, 1996). 
Over 40 years ago it was found that phencyclidine (PCP, “angel dust”), a non-
competitive NMDA receptor antagonist, exacerbates preexisting schizophrenic 
symptoms and induces a psychotic state in healthy humans that is very similar to 
that observed in schizophrenic patients (Cohen et al., 1962; Davies and Beech, 
1960; Luby et al., 1959). These observations established PCP psychosis as a 
comprehensive drug model for studying schizophrenia due to its ability to induce 
not only positive but negative symptoms and cognitive dysfunction. However, the 
link to NMDA receptor was not suspected until 30 years later when Lodge et al. 
generated evidence strongly implicated the blockade of NMDA receptors as the 
primary mechanism by which PCP disrupts brain function (Lodge and Anis, 1982; 
Davies and Lodge, 1987). Subsequent studies with other NMDA antagonists like 
ketamine and disocilpine (MK801) have led to the development of the NMDA 
receptor hypofunction model of schizophrenia (Javitt and Zukin, 1991; Olney 
et al., 1999). Administration of non-competitive NMDA antagonists to animals 
induces aberrant behaviours that are potentially related to schizophrenia including 
increased locomotor activity, stereotype behaviour, working memory deficits and 
sensorimotor gating deficits (Jentsch and Roth, 1999). 
There are several other reasons that make a NMDA receptor hypothesis of 
schizophrenia attractive. Schizophrenia is believed to have a neurodevelopmental 
component, and the NMDA receptor is critical in guiding axons to their targets 
in development (Rakic et al., 1994). Further, NMDA receptors may be important 
in processes that lead to synaptic pruning seen in adolescence, which is the age 
of onset of schizophrenia (Feinberg, 1990). Cognitive function depends on the 
plasticity mediated, in part, by NMDA receptors, and schizophrenics often have 
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cognitive deficits (Daw et al., 1993). Finally, grey matter reductions in several 
brain regions seen in schizophrenia have been suggested to be the result of 
neurotoxicity mediated by NMDA receptors (Zipursky et al., 1992). Therefore, 
a constellation of symptoms and findings in schizophrenia can be explained by 
NMDA receptor dysfunction. Recently this model is the most widely accepted 
and utilized in both humans and animals for studying neuropathology of 
schizophrenia. 
NMDA RECEPTOR HYPOFUNCTION MODEL 
Ketamine and PCP block NMDA receptors by binding to a site within the 
calcium channel of the receptor. Although this molecular action of ketamine and 
PCP is well documented, mechanisms responsible for translation of this cellular 
and molecular action into the psychotomimetic effects of the drugs are poorly 
understood. 
The electrophysiological consequences of systemic administration of NMDA 
antagonists are complex in rats, with decreased activity in sensory pathways 
(inferior colliculus, medial geniculate, and auditory cortex) and increased 
functional activity in limbic regions such as hippocampus, cingulate-, medial 
prefrontal- and retrosplenial cortex, nucleus accumbens, anterior ventral thalamic 
nucleus and amygdala (Duncan et al., 1998a-b, 1999; Kurumaji and McCulloch, 
1989). Functional imaging studies in humans after subanesthetic doses of 
ketamine have also shown neuroanatomically specific functional activation. Lahti 
et al. (1995a) found that ketamine increased blood flow in the anterior cingulate 
cortex and Breier et al. (1997) demonstrated increased 18F-flurodeoxyglucose 
(FDG) in the prefrontal cortex after infusion of subanesthetic doses of ketamine. 
Vollenweider et al. observed global increases in FDG uptake in response to 
subanesthetic doses of ketamine, but found greater increases in prefrontal cortex 
in comparison to other regions (Vollenweider et al., 1997a-b).
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By contrast, iontophoretic application of ketamine to neurons uniformly 
antagonizes NMDA-evoked excitatory responses (Anis et al., 1983; Thomson et 
al., 1985; Sinclair and Tien, 1979). The well documented ability of ketamine to 
inhibit excitatory actions of NMDA at the cellular level, and induce excitatory 
responses after systemic administration, suggests that the excitatory effects 
of ketamine result from disruption of inhibitory neural circuits (i.e. from 
disinhibition). In support of a disinhibitory action involving GABAergic 
transmission, NMDA receptors on hippocampal inhibitory interneurons were 
demonstrated to be more sensitive to an NMDA antagonist, in comparison to 
NMDA receptors on CA1 pyramidal neurons (Grunze et al., 1996). In addition, 
benzodiazepines, which potentiate GABA-mediated neurotransmission, are 
effective in reducing adverse emergence reactions following ketamine anesthesia 
(Coppel et al., 1973). Thus, components of ketamine- and other NMDA 
antagonists-induced behavioural effects may be due in part, but not wholly, to 
disinhibitory effects via reduced activity of GABA-containing neurons.
In addition to the disinhibition of GABAergic neurons, reduced autoregulation 
of glutamate release by antagonism of presynaptic NMDA receptors is another 
potential mechanism for NMDA antagonists-induced functional activation. In 
support of this latter possibility, Liu and Moghaddam (Liu and Moghaddam, 
1995) found that local infusion of NMDA antagonists into the striatum and 
hippocampus increased extracellular glutamate, suggesting a tonic inhibitory 
role of presynaptic NMDA receptors on glutamate release. Also, systemic 
administration of ketamine and PCP increased glutamate release in the prefrontal 
cortex (Moghaddam et al., 1997; Moghaddam and Adams, 1998; Lorrain et al., 
2003a). This excessive release of glutamate could then activate non-NMDA 
glutamate receptors (i.e. AMPA and kainate receptors), which in turn accounts 
for some biochemical (e.g. increased dopamine release) and behavioural effects 
of these drugs (Svensson, 2000). Accordingly, pharmacologic treatments that 
attenuate this glutamatergic activation are effective in reducing the behavioural 
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effects of PCP and ketamine. 
Indeed, administrations of AMPA/kainate receptor antagonists partially block 
behavioural effects induced by NMDA antagonists (Moghaddam et al., 1997; 
Bubser et al., 1995; Willins et al., 1993). Furthermore, treatment with mGlu2/3 
receptors agonists, both LY354740 and LY379268, has been shown to normalize 
glutamate overflow and reduce many of the behavioural abnormalities produced 
by NMDA antagonists including hyperlocomotion and cognitive deficits 
(Moghaddam and Adams, 1998; Lorrain et al., 2003b; Cartmell et al., 1999a-b). 
These data suggested that mGlu2/3 receptors agonists may represent a potential 
treatment for schizophrenia. 
SENSORIMOTOR GATING - PPI
Psychiatric researchers have searched for animal models of schizophrenia in 
order to better understand the neurobiological substrates relevant to this group of 
disorders. Because it is unlikely that a “model” of the multifaceted schizophrenia 
syndrome can be created in animals, much energy has been devoted to developing 
models of specific dysfunctions that characterize schizophrenia patients. 
The startle reflex is a collection of responses (eye-lid closure, increased heart 
rate, twitch of facial and body muscle) to sudden intense tactile, visual or acoustic 
stimulus (Figure 2). One major advantage of startle reflex paradigms is that similar 
behavioural phenomena can be studied in a variety of species including both 
humans and rodents. Despite its relatively simple and reflex-like appearance, the 
startle response serves as a valuable tool to assess different forms of information 
processing and sensorimotor response plasticity such as sensitization, habituation, 
fear-potentiation and prepulse inhibition (Koch, 1999).  
Schizophrenia patients are deficient in the normal inhibition of the startle 
reflex that occurs when the startling stimulus is preceded by a weak prestimulus 
(Braff et al., 2001). This loss of normal “prepulse inhibition” (PPI) is thought 
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to be a measure of the deficient sensorimotor gating (Braff and Geyer, 1990) 
that underlies sensory flooding and cognitive fragmentation in these patients 
(McGhie and Chapman, 1961). Similar deficits in PPI can be produced in rodents 
by pharmacological or developmental manipulation that provide models of 
sensorimotor gating deficits in schizophrenic patients with face, predictive and 
construct validity (Geyer et al., 2001; Swerdlow et al., 2001).  
There are at least four distinct PPI models based upon the manipulation used 
to disrupt PPI: dopamine agonists (apomorphine or d-amphetamine); serotonin 
agonists (DOI or MDMA); NMDA antagonists (PCP, MK-801 or ketamine) and 
developmental perturbation. Among these models, the NMDA antagonist model 
shows the greatest potential to provide insight into the unique effects of atypical 
rather than typical antipsychotics. Both typical and atypical antipsychotics restore 
PPI in apomorphine-treated rats (Mansbach et al., 2001; Keith et al., 1991; 
Swerdlow and Geyer, 1993). In contrast, only atypical antipsychotics, such as 
clozapine (Bakshi et al., 1994; Linn et al., 2003), olanzapine (Bakshi and Geyer, 
1995; Bubenikova et al., 2005) and seroquel (Swerdlow et al., 1996, 1998) could 
restore PPI in rats treated with NMDA antagonists, suggesting that this NMDA 
antagonist-induced PPI deficit might be a useful predictive measure for atypical 
antipsychotic properties.
For this model to be moved into human studies, some logistical problems must 
be overcome. Animal studies of atypical antipsychotic effects have primarily 
utilized PCP to disrupt PPI. Since PCP is a drug of abuse, there are clinical 
and ethical reasons to preclude the use of PCP in human studies. Ketamine, 
however, remains available for use in human because of its desirable anesthetic 
characteristics. Although ketamine can produce illusions, perceptual alteration, 
thought disorder and emotional blunting in human (Krystal et al., 1994; Lahti 
et al., 1995b), its effects on PPI are inconsistent. Administration of low dose 
of ketamine has been shown to either reduce (Karper et al., 1994) or enhance 
(Duncan et al., 2001; Abel et al., 2003) or has no effect on PPI (Oranje et al., 
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2002). Similarly, the initial studies of the effects of ketamine on PPI in rats 
failed to demonstrate any effect of ketamine (Mansbach and Geyer, 1989). Only 
subsequent parametric studies evaluating the importance of prepulse length and 
prepulse-pulse interval in the ketamine actions were able to show PPI deficits 
in rodents (Mansbach and Geyer, 1991). Thus, further parametric studies with 
ketamine in humans might still reveal conditions in which deficits in PPI are 
reliably observed. 
Figure 2. Diagrammatic representation of prepulse inhibition (PPI) of the acoustic startle. The top 
figure illustrates the pulse-alone trial in which startle reflex (max response 1200 g) is elicited by 
a 120 dB noise burst presented for 20-40 msec. The bottom figure illustrates the prepulse + pulse 
trial in which startle reflex (max response 650 g) is reduced by a weak prepulse given 30-1000 
msec (in this case 100 msec) before the same startle eliciting pulse used in the pulse-alone trial. 
In experiments examining tactile rather than acoustic startle, the pulse is an air-puff to the neck 
(humans) or back (rats).
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ANXIETY AND STRESS DISORDERS
Anxiety and stress has evolved biologically as a functional state and, therefore, 
both are normal and pathological. Normal anxiety/stress is a way of controlling 
the response to threatening or potentially threatening stimuli which includes not 
only the classic three “canonical” options of fight, flight, or freeze (Cannon, 1929) 
but anticipatory fear and increased level of arousal (Yerkes, 1921). Anxiety/stress 
varies in time, intensity and quality. Free-floating worry is somewhat different 
from the fearful anticipation of unwanted challenges, which is similarly different 
from the intense, short lived and irrational panic attack. These are normal 
responses under the appropriate conditions, but pathological and maladaptive if 
incongruent to the situation. Anxiety/stress disorders present in number of forms 
including panic disorder, social phobia, obsessive-compulsive disorder, post-
traumatic stress disorder and generalized anxiety disorder. Moreover, in most 
psychiatric disorders including schizophrenia, anxiety/stress is the major non-
genomic factor that contributes to the expression or exacerbation of symptoms, 
recurrence or relapse after a period of remission and treatment outcome. Although 
anxiety/stress treatments have been available for decades, the biological basis for 
these disorders in humans is just beginning to emerge.   
Since their introduction in the 1960s, benzodiazepine compounds (e.g. 
diazepam) have become the most widely used class of drugs for the treatment 
of anxiety disorders. Benzodiazepines act through the inhibitory GABA
A
-
benzodiazepine receptor complex in a unique way, by lowering the concentration 
of GABA required for opening the chloride channel (Nutt and Malizia, 2001). 
Thus, the action of benzodiazepines is markedly different from drugs such as 
barbiturates, chloral hydrate and ethanol, which can directly open the chloride 
channel. The overdose of these latter drugs could be fatal due to the inhibition 
of vital brain circuits. Apart from their efficacy, safety and tolerability, however, 
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the use of benzodiazepines is often associated with serious side effects such as 
sedation, memory impairment, ataxia, abuse potential and physical dependence 
(Woods et al., 1992). Therefore, the discovery of novel approaches to treat anxiety/
stress disorders remains an important area of neuroscience. Indeed, several recent 
reviews have focused on this issue, including the role of corticotrophin-releasing 
factor (CRH) antagonists, neurokinin antagonists, GABA
A
-selective modulators 
as well as selective serotonin-reuptake inhibitors (SSRIs) and noradrenaline-
reuptake inhibitors (Atack, 2003; Brunello et al., 2003; Gorman, 2003; Kehne 
and De Lombaert, 2002; Holmes et al., 2003; Vaswani et al., 2003).
In general, anxiety- and stress related disorders are thought of as a collection of 
illnesses that have in common excessive or inappropriate brain excitability within 
crucial brain region circuits, which leads to the expression of the symptoms. As 
glutamate is the main excitatory neurotransmitter in the mammalian brain, it is 
logical that the new approaches for treatment of anxiety/stress disorders could 




Glutamate has been implicated as a critical neurotransmitter in the 
neuroendocrine functions associated with the stress response (Brann, 1995; van 
den Pol et al., 1990). In rats, the first evidence was that glutamate injection into 
the third ventricle elevated plasma adrenocorticotropic hormone (ACTH) level 
(Makara and Stark, 1975). Administration of all subtypes of iGlu agonists had 
similar effects in later studies (Chautard et al., 1993; Jezova et al., 1991; Johnson 
et al., 2001). Thus, the evidences suggest that glutamate directly activate the 
hypothalamic-pituitary-adrenal (HPA) axis, which is a key component of the 
stress adaptation. This system responds to real or perceived threat by increasing 
the secretion of glucocorticoid hormones, such as corticosterone (cortisol in 
human). As glutamate stimulates HPA axis, blockade of glutamate transmission 
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would be expected to suppress it. In fact, iGlu antagonists could reduce the stress-
induced plasma level of ACTH and corticosterone following either peripheral 
(Zelena et al., 1999) or intracerebroventricular injection (Tokarev and Jezova, 
1997) implicating antidepressant properties. However, the role of iGlu receptors 
in regulation of HPA axis is still ambiguous. Blockade of these receptors also 
results in activation of HPA axis and subsequent rise in serum corticosterone in 
both humans and rats (Pechnick et al., 1989; van Berckel et al., 1998; Krystal et 
al., 1994).  
Preclinical work carried out about 20 years ago on MK-801, a non-competitive 
NMDA antagonist, showed that it was anxiolytic in a conditioned emotional 
response test and a simple conflict test (Clineschmidt, 1982), which initially 
supported a role for glutamatergic neurotransmission in anxiety states. Subsequent 
studies established that competitive NMDA antagonists (reversibly bind to the 
glutamate recognition site outside the ion channel), glycine-site antagonists for 
the NMDA receptors (Gly
B
 site; strychnine-insensitive modulatory site) and 
APMA/kainite receptor antagonists also possess anxiolytic properties in animal 
models (Wiley, 1997). 
Overall, the application of these iGlu receptor antagonists for treating anxiety 
in the clinics has not been successful (Danysz and Parsons, 1998). So far, 
compounds that suppress glutamate neurotransmission through an ionotropic 
receptor mechanism often produce side effects (double-sided sword) that have 
relegated their use to more severe and/or acute treatment conditions, such as 
cerebral ischaemia, head trauma, or as amnaesiac/anaesthetics. Nevertheless, 
these clinical observations indicated a role of glutamate neurotransmission in 
mediating fear/anxiety states. 
In contrast to the modulation of ionotropic glutamate receptors, relatively recent 
data indicate that mGlu receptors might have potential therapeutic application for 
anxiety. Using a broad variety of tests, both the so-called conditioned (i.e. fear-
potentiated startle, vogel test or four-plate test) and unconditioned response test 
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(i.e. social exploration, marble burying test or elevated plus maze), anxiolytic-
like effects were obtained after administration of group II mGlu receptor agonist, 
LY354740 (Table 2) as well as after administration of the mGlu5 receptor 
antagonist MPEP (Schulz et al., 2001a; Tatarczynska et al., 2001; Spooren et al., 
2000b; Johnson et al., 2001). Moreover, both compounds exhibited anxiolytic-
like effects without producing side effects such as sedation, muscle relaxation 
or impairment in learning and memory in rodents (Spooren et al., 2000b; Helton 
et al., 1998). These findings suggest that modulation of certain mGlu receptor 
subtypes may indeed represent a new and safe approach for the treatment of 
anxiety.  This is supported by recent clinical studies showing that LY354740 
reduced CO
2
-induced panic anxiety (Schoepp et al., 2003) and produced 
anxiolytic effects on fear-potentiated startle paradigm (Grillon et al., 2003), but 
no side-effects were reported.
GENDER DIFFERNCES IN PSYCHIATRIC DISORDERS
There is great evidence of gender differences in basic neural processes and 
behaviours. Brain sex-related differentiations in mammals are usually the result 
of complex interactions between the simple direct, temporary influences of 
fluctuating gonadal hormones known as activation effects, and the permanent 
organizational influences of steroid hormones: neonatal exposure to androgens 
induce masculinization, while absence of androgens, by default, result in a 
feminine phenotype (Arnold and Breedlove, 1985; McCarthy and Konkle, 2005). 
Apart from the reproductive behaviours, many non-reproductive behaviours 
such as aggression, activity level, food intake, emotional behaviour and novelty 
seeking, reflect the interdependence of different types and/or levels of sexual 
dimorphisms (Palanza, 2001).  
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Effect on mGlu2/3 receptors References 
Fear-potentiated   
Startle
Oral; �rat; 0.1-10mg/kg 
Intra-amygdala; �rat;
 0.3-1�g/side
I.p.; �rat; 0.3-3mg/kg 
Oral; ��human; 20-
200mg
Blocked expression                        
Blocked aqusition and expression 
Blocked  expression, not 
aqusition   
Blocked  expression, without 
sedation
Helton et al., 1998 
Walker et al., 2002 
Tizzano et al.,2002 
Grillon et al., 2003 
Elevated plus  
Maze 
Oral; �mouse; 1-10mg/kg 
Oral; �rat; 3mg/kg 
I.p.; �rat; 10mg/kg 
S.c.; �mouse; 20mg/kg 
Increased open-arm time 
Increased open-arm time 
Increased open-arm time 
Increased open-arm time 
Monn et al., 1997 
Helton et al., 1998 
Ferris et al.,  2001 
Linden et al., 2004 
c-Fos expression S.c.; �mouse; 20mg/kg Reduced stress-induced c-Fos in 
the  Hippocampus 
Linden et al., 2004 
Conflict tests I.p.; �rat; 0.5-1mg/kg 
I.p.; �mouse; 4-8mg/kg 
I.p.; �rat; 1-10mg/kg 
I.p.; �rat; 1-10mg/kg 
Increased shocks accepted in 
Vogel test 
Increased punished crossings in 
four-plate test 
Increased punished responding in 
select  operant schedules 
Produced temporal changes 
responding dependent on baseline 
responding
Klodzinska et al., 
1999
Benvenga et al., 
1999
Moore et al., 1999 
Lactate-induced 
Panic 
I.p.; �rat; 0.3-0.6mg/kg Blocked panic response to lactate 
infusion





I.p.; �rat; 0.03-3mg/kg 
Oral; �rat; 0.001-
0.1mg/kg
Reduced startle response 
associated with nicotine and 
diazepam withdrawal 
Helton et al., 1998 
Immobilization 
Stress 
S.c.; �rat; 30mg/kg Reduced immobilization-induced 
increase in NA and DA in 
prefrontal cortex dialysated 





I.p.; �rat; 0.1mg/kg Normalized the latency and the 
time spent in the light of 
preshocked rats 





I.v.; �macaque; 1mg/kg Prevented yohimbine increased 
cortisol and  
MHPG level 
Coplan et al., 2001 
CO2-induced
anxiety/panic 
Oral; human; 200mg BID Prevented  CO2-induced anxiety 
in panic patients 




Oral; human Reduced anxiety (HAM-A) 
compared with placebo 
Schoepp,  2004 
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Sex differences in brain and hormone levels are not only of the importance 
for behaviour, but are also thought to be the structural and functional basis of 
the often pronounced sex differences in the prevalence of neurological and 
psychiatric diseases.  It is generally acknowledged that alcoholism and other drug 
abuse, antisocial personality, attention deficit disorders, Tourette’s syndrome and 
completed suicide predominate in men, whereas depression, anxiety, eating 
disorders, and attempted suicide are more common in women (Jablensky et 
al., 1992; Rutter, 1995; Blehar, 1995; Hanna and Grant, 1997). Panic with 
agoraphobia, generalized anxiety disorder (GAD) and posttraumatic stress 
disorder (PTSD) occur two to three times more frequently in women than in men 
(Yonkers et al., 1996; Gater et al, 1998). Gender differences in schizophrenia are 
also observed and are probably due to the neuroprotective properties of estrogens. 
The onset of schizophrenia in men is between 15 and 24 years while in women 
3–4 years later (Hafner et al., 1993). Women present with a second increase of the 
incidence between 45 and 54 years, which has been attributed to the beginning of 
the menopause (Hafner et al., 1993).
In addition to the female prevalence in depression/anxiety, there are gender 
differences in presentation, course of illness and treatment response to both 
medication and psychotherapy (Frackiewicz, 2000). Women may have an 
enhanced response to non-tricyclic antidepressants, necessitating the need to 
vary dosages or drug class selections based on the sex of the depressed patients 
(Yonkers et al., 1992). The response to antipsychotic drugs, women requiring 
lower doses on a milligram per kilogram basis, may also be different as a result 
of hormone concentrations or receptor densities (Yonkers et al., 1992). Estradiol 
can exert profound effects on mood by acting on neurotransmitter systems 
that are implicated in depression and anxiety; for instance, decreased levels of 
estrogen are accompanied by depression and women with persistent depression 
are effectively treated with estrogen (Fink et al., 1996; Gerrits et al., 2005). 
Although findings are inconsistent, animal studies also suggest that sex 
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differences exist in fear and anxiety-related behaviours in the open-field test, 
the elevated plus maze, the social interaction test, the defensive prod-burying 
test, acoustic startle reflex and conflict procedures (Steenbergen et al., 1991; 
Fernandez-Guasti and Picazo, 1992, 1997; Stock et al., 2000; Westenbroek et al., 
2003). Male rodents generally exhibit more fear-related behaviours than females, 
although some studies fail to see sex differences in specific tests (Frye et al., 
2000; Marcondes et al., 2001) or have demonstrated the opposite sex difference 
in “anxiety-like” behaviours (Johnston and File, 1991). The ability of gonadal 
hormones, neurosteroids such as 3α5α tetrahydroprogesterone (3α5αTHP), and 
the estrous cycle to modulate responses in these anxiety models contribute to the 
notion that males and females show differing levels of anxiety-related behaviours 
based on their differing hormonal milieus (Johnston and File, 1991; Zimmerberg 
and Farley, 1993; Frye et al., 2000; Marcondes et al., 2001). 
Accordingly, significant anxiolytic drug x gender interactions were 
consistently obtained in a high proportion of those rare studies in which male and 
female subjects were compared (Fernandez-Guasti and Picazo, 1990, 1997, 1999; 
Alonso et al., 1991; Barros and Ferigolo, 1998; Diaz-Veliz et al., 1997; Blanchard 
et al., 1991), thus indicating sexual differentiation in responses to psychoactive 
drugs. Nevertheless, only an extremely small proportion of basic researches on 
anxiety and anxiolytic drugs have focused on female rats or mice as experimental 
models. Females as subjects in behavioural research are often neglected because 
they are thought to be too ` variable’, and it is easier and cheaper to use only males 
(Blanchard et al., 1995). Similarly, all studies focused on anxiolytic action of 
mGlu receptors modulation involved only males.
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SCOPE OF THE THESIS
In the last decade the targeting of mGlu2/3 receptors have become a 
promising strategy to develop new treatments for psychiatric disorders including 
schizophrenia and anxiety. Since this is a relatively new discovery, the available 
preclinical data are either conflicting or incomplete. In this regard, the studies 
presented in this thesis are designed to explore the possible therapeutic role of 
mGlu2/3 receptors by using two selective mGlu2/3 receptor agonists, LY354740 
and LY379268 (Figure 3).
Figure 3.  Chemical structures of 
the group II mGlu receptor agonists 
LY354740 and LY379268.
OUTLINE
   
Chapter 2 describes the experiments that were designed to establish the dose-
response characteristic effects of ketamine on locomotion, sensorimotor gating, 
working memory and c-fos expression throughout the brain. The results provide 
a comprehensive overview about the wide-ranging behavioural and neuronal 
disturbances evoked by ketamine. The dose 12 mg/kg of ketamine appeared to 
induce all aspects of this schizophrenia model.
 Chapter 3 presents that subchronic pretreatment with LY354740 failed to 
prevent ketamine-evoked hyperlocomotion, PPI deficits and c-fos expression. C-
fos expression in the hippocampus indicated a selective effect of LY354740 on 
neuronal activity that might be related to its anxiolytic properties. 
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In chapter 4 the effects of acute pretreatment with LY379268 on the ketamine 
model are described. LY379268 could prevent hyperlocomotion but not PPI deficit 
evoked by ketamine. HPLC analysis in the dentate gyrus showed that LY379268 
could prevent the ketamine effect on glutamate but not on monoamines systems. 
Administration of LY379268 per se had dose-dependent anxiolytic/anxiogenic 
effects. 
In chapter 5 anxiolytic properties of LY354740 and LY379268 were studied 
in males and females using traditional and fear-potentiated elevated plus maze 
test. As a plasticity marker, the expression of pCREB/CREB in the dentate gyrus 
was analyzed  by western blotting. Gender differences in behavioural and protein 
parameters are described. 
 The general discussion (Chapter 6) puts the results in a broader perspective 
and addresses further propects.         
2
Dose-response characteristics of ketamine effect on 
locomotion, cognitive function and central neuronal 
activity 
Gabor Imre, Dirk S. Fokkema, Johan A. Den Boer, Gert J. Ter Horst.




The present dose-response study sought to determine the effects of subanesthetic 
dosages (4-16 mg/kg) of ketamine on locomotion, sensorimotor gating (PPI), 
working memory, as well as c-fos expression in various limbic regions implicat-
ed in the pathogenesis of schizophrenia. In addition, we examined whether keta-
mine-induced locomotion was influenced by the dark/light cycle. We found that 
ketamine increased locomotor activity in a dose dependent manner, but found 
no influence of the dark/light cycle. Additionally, ketamine dose-dependently 
interrupted PPI, resulting in prepulse facilitation at doses of 8 and 12 mg/kg. 
The dose of 12 mg/kg also induced impairments in working memory assessed by 
the discrete-trial delayed-alternation task. C-fos expression indicated that the 
dose-dependent behavioral effects of ketamine might be related to changes in 
the activity of limbic regions, notably hippocampus and amygdala.
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INTRODUCTION
 A widely accepted and utilised psychopharmacological model of schizophrenia 
is based on the effect of non-competitive NMDA receptor antagonists, such as 
phencyclidine (PCP), dizocilpine (MK801) and ketamine (Javitt and Zukin, 1991; 
Olney et al., 1999).  A subanesthetic dose of ketamine produces several behavioural 
abnormalities in rodents such as disruption of sensorimotor gating (PPI) and 
working memory, which are analogous to the effects of ketamine in humans and 
mimic the symptoms of schizophrenic patients (Jentsch and Roth, 1999; Krystal 
et al., 1994; 2002; Mansbach and Geyer, 1991; Verma and Moghaddam, 1996). 
Such experimentally induced deficits provide a model with significant face, 
predictive and construct validity (Jentsch and Roth, 1999). Ketamine and other 
NMDA antagonists also increase locomotor activity in rodents, but not in humans 
(Jentsch and Roth, 1999). Thus, the relationship between rodent hyperlocomotion 
and schizophrenic symptoms lacks a proper degree of face validity (Schulz et al., 
2001b). However, because locomotor activity is associated with limbic-striatal 
function, ketamine-induced hyperlocomotion might be indirectly linked to 
schizophrenia since the latter is generally associated with limbic abnormalities 
(Takahata and Moghaddam, 2003). 
The mechanism by which ketamine produces its adverse behavioural effects, 
at least partly, have been attributed to the blockade of NMDA receptors located on 
inhibitory GABAergic neurons limbic and subcortical brain regions (Duncan et 
al., 1998a; Moghaddam and Adams, 1997; Nakao et al., 2003). This disinhibitory 
action leads to increase in the neuronal activity and excessive glutamate and 
dopamine release in the prefrontal cortex and limbic striatal regions (Duncan et 
al., 1998a; Gao et al., 1998; Gass et al., 1993; Lorrain et al., 2003a; Moghaddam 
and Adams, 1997). In these studies, however, a higher dose range (10-35 mg/kg) 
was used, compared to the studies in which the behavioural effects of ketamine 
(2.5–12 mg/kg) were investigated (Mansbach and Geyer, 1991; Pallares et 
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al., 1995; Silvestre et al., 1997; Swerdlow et al., 1998). Although Nisizawa 
et al. (2000) found a strong correlation between ketamine-induced locomotor 
responses and cell activity measured by c-fos expression, this study investigated 
only posterior cortical areas using considerably high doses of ketamine (20-
50 mg/kg). Thus, the question arises which are the links between behavioural 
changes (hyperlocomotion and cognitive deficit) and brain activity induced by 
the lower doses of ketamine.
 In Experiment 1, subanesthetic doses of ketamine (4-16 mg/kg) were used 
1) to characterise the nature and time course of its effect on the locomotion 2) 
to define neuroanatomical regions where this treatment regime would affect 
neuronal activity assessed by c-fos expression 3) and to investigate the correlation 
between behavioural changes and c-fos expression. Since rats are nocturnal 
animals, locomotor activity is more abundant in the dark phase of the dark/light 
cycle (Westenbroek et al., 2003), Nevertheless, behavioural studies investigating 
the locmotor activating effects of stimulants have been conducted during the light 
phase (i.e. the sleeping period) or do not mention this  experimental conditions. 
Thus, we also compared the effects of ketamine on locomotion under different 
light conditions.
 In a second study (Experiment 2) the dose-response characteristic of ketamine-
evoked (4-12 mg/kg) cognitive deficits were assessed using two behavioural 
measures which are likely to have relevance to clinical symptomology: the 
prepulse inhibition of the startle reflex paradigm (PPI) and the discrete-trial 
delayed alternation task. PPI refers to the phenomenon that a weak stimulus 
(prepulse) reduces the behavioural response to a second, more intense, stimulus. 
PPI provides an operational measure of sensorimotor gating both in human 
and rodents (Geyer et al., 2001). The discrete-trial delayed alternation task is 
a working memory-related paradigm. Performance of this task depends on the 
functional integrity of the prefrontal cortex, and it is sensitive to the acute effects 
of psychostimulants (Aultman and Moghaddam, 2001). 





Twenty-five male Wistar rats (Harlan, The Netherlands) weighing 248±8 g (5-6 weeks of age) at 
the start of the experiments were individually housed in plexiglas cages (45×28×20 cm) on a 12/
12 h light/dark cycle (lights on at 7:00). After the second open field test, the light/dark cycle was 
reversed (lights on at 19:00) and animals were allowed to acclimate to it for a period of 1 week. A 
piece of PVC tube (d=8 cm, l=17 cm) was provided in the home cage as a shelter. Food (standard 
rat chow, Hopefarms) and water were available ad libitum. All animals were handled and weighed 
daily to minimise stress during the experiment. The Animal Ethics Committee of the University of 
Groningen approved the protocol (FDC: 2935).  
LOCOMOTOR BEHAVIOUR 
Open field tests (OF) were performed under both day-light (sleep period) and red-light (active 
period) condition in order to compare the effect of ketamine (Sigma, Germany) on locomotion in 
the inactive period with the active period of the animals. The open field consisted of a circular black 
arena with a diameter of 1 m. Rats were placed in the centre of the field at certain time points i.e. at 
0, 20, 40, 60 and 90 min post saline or ketamine (4, 8, 12, 16 mg/kg) injection (s.c.) and observed 
for a period of 5 min. This test was repeated 4 times, each performed 1 week apart: every rat served 
as its own control therefore each received a saline injection followed by a ketamine challenge under 
both normal- and reversed-light condition (Table 1). Five animals received only saline during this 
protocol in order to get control brain activity for c-fos comparison. Locomotor behaviour was 
recorded with a videotracking system (Etho Vision, 1.96, Noldus Information Techonology, 
Wageningen, The Netherlands). The distance moved within the arena was analysed. 
Table 1.  Experimental protocol for open field-locomotor behaviour.
IMMUNOHISTOCHEMISTRY
The rats were euthanized 2 h after the last ketamine injection using sodium pentobarbital anesthesia 
(1 ml, 6%) and  perfused with 50 ml heparinised saline and 300 ml of 4% paraformaldehyde 
solution in 0.1 M sodium phosphate buffer (pH 7.4). The brains were removed and postfixed in the 
same fixative overnight at 4°C. Following an overnight cryoprotection in a 30% sucrose solution, 
serial 40 μm coronal sections of the cerebrum were made with a cryostat microtome and collected 
in 0.02 M potassium phosphate saline buffer (KPBS). Fos immunostaining was performed as 




 for 10 min 
the sections were thoroughly washed with KPBS and incubated with rabbit anti-Fos antibody (1:
10000; Oncogene Research Products, San Diego, CA, USA) diluted in 0.02 M KPBS with 0.25 
%
 
Triton X-100 and 2% normal goat serum for 72 h at 4°C. After washing, the sections were 
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and avidin-biotin-peroxidase complex (Vectastain ABC Elite Kit, Vector Laboratories, Burlingame, 
CA, USA). After thorough washing, the peroxidase reaction was developed with DAB-nickel 




Sections were washed for 15 min in buffer and mounted with gelatine 
solution and air-dried, dehydrated in graded alcohol and xylol solutions and then coverslipped with 
DePeX mounting medium (BDH).
In order to avoid differences in staining intensities, sections were stained according to the same 
procedure. The c-fos labelled cells were quantified using computerized image analysis system by 
an observer who was blind to group assignment.  The area of the region of interest (ROIs) was 
digitized using a Sony (SONY Corporation, Tokyo, Japan) chargecoupled device digital camera 
mounted on a LEICA Leitz DMRB microscope (Lecia Qwin version 2.3, Leica Microsystems 
Imaging Solutions, Wetzlar, Germany). The number of immunopositive nuclei was quantified in a 
single focus plane (at ×100) for each ROIs, which were outlined with digital pen and each digitized 
image was individually set at a threshold to subtract the background optical density. The average of 
immunoreactive cells was expressed as number of positive nuclei/0.1 mm2.
Experiment 2
ANIMALS
Twenty-four male Wistar rats (Harlan, The Netherlands) weighing 210±5 g (4-5 weeks of age) 
at the start of the experiments were individually housed in plexiglas cage (45×28×20 cm) with a 
12/12 h light/dark cycle (lights on at 7:00). A piece of PVC tube (d=8 cm, l=17 cm) was provided 
in the home cage as a shelter. All animals were handled and weighed daily to minimise handling 
stress during the experiment. Food was available ad libitum two weeks following arrival, after 
which they were placed on restricted diet of 15 g per day per rat. The rats had ad libitum access to 
water throughout the duration of the experiment. The Animal Ethics Committee of the University 
of Groningen approved the protocol (FDC: D4116A).  
PREPULSE INHIBITION OF THE STARTLE REFLEX (PPI)
After 1 week of acclimatization PPI tests were conducted using a TSE Startle Response Measuring 
System (Technical and Scientific Equipment GmbH, Bad Homburg, Germany). The rats were 
restrained in a small cage (27×10×12.5 cm) and placed on a transducer platform that registers 
movement. Acoustic stimuli were generated by means of high-quality high-linearity speakers 
situated on both sides of the cage. The whole setup was operated in a sound-attenuating isolation 
chamber equipped with a ventilation fan and house light. An IBM-compatible computer with TSE 
Startle Response software and control interface was used to present stimuli and record data.
 Following saline or ketamine (4, 8 and 12 mg/kg s.c.) injection, the rats were placed in the startle 
box for a 5-minute acclimatization period with a 70 dB background noise. This noise continued 
throughout the session. 
The test session consisted of four trial types:  (1) SP alone:  rats were exposed to 120 dB 40-ms 
startle pulse; (2) PP+SP: startle pulse preceded 100 ms earlier by 85 dB 20-ms prepulse (3) PP 
alone: prepulse alone; (4) no-stimulus: background noise only. One session consisted of 35 trials, 
with 3 consecutive sp alone trials in the beginning and 32 subsequent trials (each trial types 8 times) 
presented in a random order, with 15 s average (range 10-20 s) intertrial interval. 
PPI was defined as the percentage reduction in mean startle response magnitude (SRM) in the 
presence of the prepulse compared to mean SRM in the absence of the prepulse: 100-[100*(mean 
SRM PP+SP trials/ mean SRM SP alone trials)]. The 3 SP alone trials, which were presented at the 
beginning of the test session to achieve a relatively stable level of startle reactivity for the remainder 
of the session (based on the observation that the most rapid habituation of the startle reflex occurs 
within the first few presentations of the startling stimulus, {Geyer et al., 1990}), were not included 
in the calculation of PPI values. 
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DISCRETE PAIRED-TRIAL DELAY T-MAZE TASK
The test was conducted in a T-maze that was made of wood and the arms were covered with grey 
plastic. The main alley, 80×20×13 cm, was connected to two goal arms, each 40×20×13 cm. Two 
sliding doors were manually operated to close off either goal arm. At the end of each goal arm, a 
3-cm high piece of metal blocked the food reward from view. During the inter-trial and the intra-
trial periods, animals were confined in a holding box (20×20×13 cm) which was separated from 
the main alley by a sliding door. The experiments were performed in the light period between 8:
00 a.m. and 12:00 a.m. The testing room was illuminated by three 25-W lamps positioned around 
the maze. 
The training protocol was adapted from Aultman and Moghadam (2001). One week after the PPI 
test, the animals were placed on food restriction and were introduced to the food reward (yoghurt 
drop, Vitakraft) in their home cage. After that rats were habituated to the T-maze. On the first day 
of habituation, rats were placed in the maze individually and allowed to explore freely for 5 min. 
Food rewards were scattered throughout the maze. Subsequently, only the ends of the two goal arms 
were baited. This procedure continued until the rats ran quickly to both goal arms and consumed the 
food (2-3 days). This was followed by one week of “forced alternation” training, where rats were 
allowed to retrieve the reward from only one arm, the other being blocked. Rats were given ten 
trials each day; on five trials the rat was forced to enter the right goal arm and on five the left, in an 
alternating pattern. A 10-s inter-trial interval separated these trials.
Following the forced alternation training, the discrete, paired-trials delayed alternation task began. 
Each trial-pair consisted of a forced trial and a choice trial, separated by a delay interval of 10 
s (memory retention). In forced trial the rat had access to only one goal arm, which was baited. 
Following consumption of the reward, the rat was removed to the holding box for the delay. In 
choice trial the rat has access to both goal arm, but only the previously blocked arm contained the 
reward. Correct choice was scored if the rat entered the baited arm; entries into the initially visited 
forced arm were scored as errors. Trial-pairs were separated by 30s inter-trial interval. Each test 
block consisted of ten trial pairs. A different, randomly chosen, pattern of forced trials, but no more 
than two consecutive forced entries in a given direction (e.g. R-L-R-R-L-L-R-L-R-L), was used 
every day (on a given day the same pattern for all animals). This training continued until the rat 
successfully performed seven out of ten trials (70%, 7-10 days) for three consecutive days. Upon 
reaching a stable performance level, the animals randomly received a saline or ketamine injection 
(8 and 12 mg/kg s.c.). According to the duration of action on the locomotion as established in 
Experiment 1, ketamine was applied 10 min (8 mg/kg) and 25 min (12 mg/kg) prior to testing in 
order to avoid the locomotor effects of ketamine which might influence the performance in the T-
maze.
STATISTICAL ANALYSIS 
Statistical analyses were done with SPSS (version 10), and P<0.05 was considered significant. 
Locomotor activity was analysed with repeated measures ANOVA, with time point as within subject 
factor and treatment and light condition as between subject factors. T-maze performance was also 
analysed with repeated measures ANOVA, with ketamine treatment being specified as between 
subject factor and consecutive days (4 days) as within factor. Sphericity assumed modelling, with 
Huynh-Feldt adjustment, was applied. C-fos and PPI were analysed with univariate ANOVA with 
dose as a between subject factor. An LSD post hoc test was used for the pairwise comparisons. 
Correlative studies between the ketamine induced locomotion under red-light condition and c-fos 





LOCOMOTOR BEHAVIOUR   
       Under both light conditions, at all dosages of ketamine rats displayed the 
characteristic behavioural responses of side-to-side head rocking, arching of the 
neck and staggered locomotion. Overall ANOVA showed a significant ketamine 
main effect (F (3, 32) =4.000, P<0.016). The stimulatory effects of ketamine were 
dose-dependent to the extent that the higher doses produced a longer duration of 
the response as illustrated in Fig. 1. There was a significant main effect of time (F 
(3, 124) =46.631, P<0.001) and time×ketamine interaction (F (11, 124) =5.292, 
P<0.001).
As repeated measures ANOVA revealed, when the rats were tested under day-
light condition only the highest dose (16 mg/kg) caused significant changes in 
locomotion during the first trial (t=0, P<0.002), which lasted for 20 min (t=20, 
P<0.001) and reached baseline activity after 40 min. The shape of the curve is 
similar in the 12mg/kg group, however it failed to be significant during the first 
trial (t=0, P<0.169; t=20, P<0.019). At the dose 4 and 8 mg/kg ketamine slightly 
increased locomotion in the first 5 min and the locomotor activity reached the 
baseline level again before the second trial.
Under the red-light condition, except the 8 mg/kg dose, every dose increased 
locomotion significantly in the first trial (t=0, 4 mg/kg P<0.015; 12 mg/kg 
P<0.001 and 16 mg/kg P< 0.001). During the second trial hyperactivity remained 
significantly high in groups receiving the 12 mg/kg (P<0.007) and 16 mg/kg 
dose (P<0.002). After this excitatory effect the activity fell under the baseline 
level, which was significant at dose 12 mg/kg and 16 mg/kg (t=40, P<0.005 and 
P<0.017 respectively). 
Altering the light/dark cycle did not influence the locomotor activity in 
the open field. There was no main effect of light condition (F (1, 32) =1.865, 
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P<0.182), nor light condition×ketamine interaction (F (3, 32) =0.19, P<0.996). 
Because of the hyperlocomotion effect of ketamine is apparent at t=0 and t=20, 
statistical analysis were repeated for these two time points excluding the results 
at t=40, t=60 and t=90. In this analysis, similarly to the overall ANOVA, there 
was ketamine main effect (F (3, 32) =6.166, P<0.002) but no light condition (F 
(1, 32) =1.322, P<0.259) and no light condition×ketamine interaction (F (3, 32) 
=0.081, P<0.970); therefore all rats were sacrificed during the red light period for 
subsequent c-fos determinations. 
Figure 1. Effect of different doses of ketamine on locomotion (n=5). Hyperlocomotion evoked 
by ketamine expressed as relative total distance moved (∆cm): difference in total distance moved 
between ketamine and saline control test.
#P<0.05; significant increased locomotion by ketamine under normal light condition.
*P<0.05; significant increased locomotion by ketamine under reverse light condition.




C-fos expression was analysed in brain regions which are involved in the 
pathophysiology of schizophrenia such as prefrontal-, (PFC) retrosplenial- 
(RS) and entorhinal cortex (EC) and limbic regions (hippocampus, striatum 
and amygdala). In addition, the hypothalamic paraventricular nucleus (PVN) 
and dorsomedial nucleus (DMH) was analysed since they are associated with 
stress responses.The ketamine treated animals showed significantly higher c-fos 
expression in various brain areas compared to saline-treated controls. As illustrated 
in Table 2, ketamine dose-independently increased the number of c-fos labelled 
cells in the PFC ([ACAd]: F (4, 20) = 4.329, P<0.001, 262-312%; [ILA]: F (4, 
20) =20.700, P<0.001, 255-283%; [PL]: F (4, 20) =10.705, P<0.001, 258-311%), 
RS (F (4, 20) =13.711, P<0.001, 340-489%) and NAc (F (4, 20) =4.411, P<0.05, 
176-218%).There was no main effect in the EC (F (4, 20) = 1.882, P<0.155) 
and CP (F (4, 20) =2.144, P<0.113). In the amygdala ([CeA]: F (4, 20) =20.069, 
P<0.001; [BlA]: F (4, 20) =6.343, P<0.01), hippocampus ([DG]: F (4,20) =4.150, 
P<0.05; [CA1]: F (4, 20) =5.409, P<0.01; [CA3]: F (4, 20) =8.690, P<0.001) 
and the hypothalamus ([PVN]: F (4, 20) =25.329, P<0.001; [DMH]: F (4, 20) 
=3.179, P<0.05) ketamine induced dose-dependent changes in c-fos expression. 
In the central amygdala, the CA1 and the CA3 regions the lowest dose (4 mg/kg) 
of ketamine induced changes in c-fos expression that were significantly higher 
(901%, 634% and 473% respectively) than other doses (531-636%, 336-364% 
and 288-333%). In general, increasing doses tend to induce less staining (Fig. 
2). However, in the PVN 4 mg/kg induced a significantly lower c-fos response 
(347%) compared with the higher doses (445-464%). Noteworthy is that with the 
highest dose, the number of c-fos positive cells was lower than with intermediate 
doses in most brain areas and did no longer differ significantly from the baseline 
in hippocampus (147%) basolateral amygdala (164%) and DMH (155%). 
As the Kendall rank correlation test showed there was no significant correlation 
between ketamine-induced hyperlocomotion and c-fos expression (Table 2).
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Table 2. C-fos expression in the investigated brain areas Mean number of c-fos positive cell per 0.1 
mm2 ± SEM.*P<0.05, **P<0.01; ketamine compared with saline. #P<0.05; 4 mg/kg of ketamine 
compared with other doses. Kendall rank correlation tests do not show significant correlations 
between ketamine-induced hyperlocomotion and c-fos expression.
Figure 2.
Photomicrgraphs 
i l l u s t r a t i n g 
k e t a m i n e -
induced c-fos 
immunoreactivity 
in the central (CeA) 
and basolateral 
(BlA) amygdala.
Scale bar = 50 μm
             Saline      4mg/kg        8mg/kg          12mg/kg       16mg/kg      Kendall �
PFC
Cingulate, ACAd              56±9         147±8**       174±9**       158±7**       161±10**       -0.242      
Imfralimbic, ILA                 42±7         115±6**       119±7**       107±6**       108±4**         -0.053 
Prelimbic, PL                       46±11       121±5**       142±13**     134±5**       118±6**         -0.074 
Retrosplenial cortex, RS      35±14       139±7**       170±19**     151±13**     118±15**       -0.263 
Hippocampus 
CA1                                      15±8          95±20**#     55±6*           54±14*         51±9             -0.123 
CA3                                        8±3          42±4**#        30±5**        27±2 **        26±5**         -0.205 
Dentate gyrus, DG                32±6          61±7*           42±2            52±6*           47±4               0.006 
Entorhinal cortex, EC           50±4          46±9             69±9            72±13           73±15            -0.181 
Striatum 
Nucl. accumbens, NAc          53±7          93±15*       107±11**     116±8 **       97±8*            0.018 
Dorsal striatum, CP                21±3         43±7             47±3             38±6            45±7             -0.116 
Amygdala 
Basolateral, BlA                    14±4         29±1**         32±3**           23±2*         22±3             -0.298 
Central, CeA                           6±1         52±5**#        37±3**          36±4**       31±4**         -0.193 
Hypothalamus 
Paraventricular n., PVN          6±2         21±2**#       26±2**           28±1**       27±2**          0.099 




PREPULSE INHIBITION OF THE STARTLE REFLEX (PPI)
One-way ANOVA showed a significant main effect of ketamine on PPI (F 
(3, 20) =8.146, P<0.001) as well as on the startle magnitude (SRM) in sp alone 
trials (F (3, 20) =6.268, P<0.001) As illustrated in Fig. 4, all doses of ketamine 
significantly reduced PPI (P<0.001) and resulted in prepulse facilitation (PPF) 
at doses of 8 and 12 mg/kg. There was a significant increase in SRM by 4mg/kg 
compared to control (P<0.005), whereas the higher doses did not alter SRM.
Figure 3. Effects of ketamine on the prepulse inhibition (PPI) and the startle response 
magnitude(SRM). All doses of ketamine significantly impaired the PPI (n=6). In the 4 mg/kg 
condition PPI was reduced significantly concurrent with a significant increase in a SRM. The 
negative PPI value at the doses of 8 and 12 mg/kg represent prepulse facilitation without significant 
changes in the SRM. *P<0.05; significant changes in PPI and in SRM compared with control.
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DISCRETE PAIRED-TRIAL DELAY T-MAZE TASK
Injection of saline, after rats reached the criterion, did not influence the 
number of correct response as illustrated in Fig. 4. Repeated measures ANOVA 
revealed a main effect of ketamine treatment on the performance (F (2, 17) 
=9.324, P<0.002). Ketamine at 12 mg/kg significantly reduced the percentage of 
correct responses compared to control (P<0.001). The lower dose of ketamine did 
not affect the performance. 
As mean velocity indicated (measured in the main alley), ketamine had no 
effects on locomotion during the test in the T-maze (Fig. 4, inset; F (2, 17) 
=0.373, P<0.696).
Figure 4. Effects of ketamine on working memory. After reaching the criterion (7 correct choices 
out of 10 for 3 consecutive days) animals (n=6-7) received the ketamine injection 10 min (8 mg/kg) 
and 25 min (12 mg/kg) prior to test respectively on the 4th day.  At the dose of 12 mg/kg ketamine 
significantly impaired the performance. (*P<0.05). During the test, ketamine had no longer effect 




 The hyperlocomotion evoking effects of NMDA antagonists have been 
well characterized (de Leonibus et al., 2001; Jentsch and Roth, 1999; Lorrain 
et al., 2003a). Our findings replicated and extended these previous reports by 
demonstrating that ketamine increased the locomotion dose-dependently as that 
the effect of the highest doses (12-16 mg/kg) lasted at least 25 min, whereas the 
non-significant effect of the lower doses (4-8 mg/kg) was confined to the first 5 
min. In addition, we showed that this ketamine-induced hyperlocomotion is not 
influenced by the light/dark cycle. With an exception of the lowest dose (4 mg/kg) 
which could induce significant hyperactivity during the animals’ active phase, but 
not in day-light condition, the locomotor behaviour was similar irrespectively of 
light condition for every dosage of ketamine. This implies that the light cycle was 
irrelevant for the locomotor activity in the present setup and therefore the further 
behavioural tests were conducted under day-light condition. 
In accordance with the literature (Mansbach and Geyer, 1991; Swerdlow et 
al., 1998; Verma and Moghaddam, 1996), ketamine induced a dose-dependent 
deficit in PPI and working memory. In fact at the doses of 8 and 12 mg/kg 
ketamine elicited prepulse facilitation (PPF) without affecting the startle 
response magnitude (SRM), while 4 mg/kg increased SRM resulting in reduction 
of PPI. Additionally, at the dose of 12 mg/kg ketamine impaired working memory 
assessed by discrete-trial delayed alternation task, whereas the lower dose (8 mg/
kg) had no effect on the performance.
 PPI is regulated by highly interconnected cortico-limbic systems and is 
therefore particularly sensitive for disruption of the homeostasis of this network 
(Swerdlow et al., 2001). Thus, low doses of ketamine, which are not able to 
induce hyperlocomotion or working memory deficit, could produce significant 
disruption in PPI resulting in PPF. Under normal conditions PPF occurs either at 
low (0-30 ms) or large (>800 ms) prepulse-startle interval (PSI) (Reijmers and 
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Peeters, 1994a-b) and this facilitation can be enhanced by ketamine (Mansbach 
and Geyer, 1991). Moreover, 10 mg/kg ketamine was shown to evoke PPF at 
the interval 100 ms when normally prepulse inhibition is observed (de Bruin et 
al., 1999). Based on these findings it has been suggested that PPI and PPF are 
two different mechanisms, where the facilitatory process normally is suppressed 
by the concurrent inhibition and that ketamine could selectively disrupt the 
inhibitory mechanisms, thereby unmasking the facilitatory process (Mansbach 
and Geyer, 1991). It can be argued that in the present experiment at the doses of 8 
and 12 mg/kg ketamine produced maximal reduction of the inhibitory processes 
which in turn manifested as PPF.
As previously reported, ketamine could produce working memory deficit in 
spatial delayed alternation task at the dose of 20-30 mg/kg but not 10 mg/kg (Verma 
and Moghaddam, 1996). Here we demonstrated that dose of 12 mg/kg ketamine is 
also able to impair working memory. It is likely that methodological differences 
account for this inconsistency of dose response. The main disadvantage of the 
traditional delayed-alternation task is the overtraining, which in turn requires 
long inter-trial delays (up to several minutes) in order to observe treatment effects 
on the performance that may not represent working memory deficit but impaired 
task acquisition. Another confound of this task is that the performance of the 
animal continuously improves with training and therefore it might be difficult 
to reach a stable baseline performance. In contrast, in the discrete-trial delayed 
alternation task animals reach a steady, delay dependent performance as that the 
rats performed significantly worse at the longer delay interval than short retention 
time supporting the hypothesis that this task assesses working memory (Aultman 
and Moghaddam, 2001). Thus, the discrete-trial delayed alternation task provide 
more sensitive measurement for the acute effects of psychostimulants on working 
memory which might explain that such a low dose of ketamine was found to 
impair the percentage of correct responses in this task. It should be noted that 
the T-maze tests were performed only at a delay interval of 10 s. Therefore, we 
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cannot rule out the possibility that 8 mg/kg or lower doses may lead to working 
memory deficit at longer memory retention.
Since the hyperlocomotion effect of ketamine might affect the performance of 
the animals in the T-maze, tests were conducted after the peak effect of ketamine 
on locomotion i.e. 10 (8 mg/kg) and 25 (12 mg/kg) min respectively. The lack 
of significant difference in the mean velocity between the ketamine- and saline-
treated groups in the present study suggest that  ketamine-induced impairment 
of the discrete-trial delayed alternation task cannot be attributed primarily to 
interference by locomotor activity; rather, a disruption in associative function 
might have occurred. 
Ketamine and other NMDA antagonists have been consistently reported to 
induce c-fos expression in the cortical areas (prefrontal and retrosplenial cortex), 
nucleus accumbens (NAc), amygdala and the hypothalamus (Duncan et al., 
1998a; Gao et al., 1998; Gass et al., 1993; Sharp, 1997; Szakacs et al., 2003). 
Similarly, in the present study ketamine increased the number of c-fos positive 
cells within these areas irrespectively of doses. In contrast to these studies, we 
also found significant ketamine-evoked c-fos expression in the subregions of the 
hippocampus (CA1, CA3 and DG) which was dose-dependent to the extent that 
the 4mg/kg ketamine produced higher expression compared to the other doses, 
whereas increasing doses gradually decreased this expression. Similar c-fos 
pattern was observed in the central nucleus of amygdala (CeA). Nevertheless, the 
c-fos expression in all brain areas investigated in this study did not correlate to 
the dose-dependent effect of ketamine on the locomotion.
Our finding concerning the inverse dose-dependent c-fos induction in the 
hippocampus and CeA is in accord with earlier report demonstrating that 
dizocilpine (MK801) up to 2 mg/kg increased c-fos in the hippocampus and then 
c-fos level declined from a dosage of 4 mg/kg (Ahn et al., 2002). The former 
effect may be due to the indirect activation of excitatory neurotransmitter systems 
as a consequence of reduced activity of GABA-containing neurons, whereas the 
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latter effect is possibly a direct NMDA receptor blockade on excitatory neurons 
which might also lead to reduction in c-fos induced by its own activating effect. 
NMDA receptors on hippocampal inhibitory neurons were found to be more 
sensitive to an NMDA antagonist, in comparison to NMDA receptors on CA1 
pyramidal neurons (Grunze et al., 1996). Thus, at a low dose of ketamine, a 
preferential reduction of inhibitory tone would be expected resulting in high c-fos 
expression in the hippocampus which can be reduced by blocking the excitatory 
neurons at higher dosages.  
According to the model of Grace (2000), glutamatergic afferents from the 
amygdala and the hippocampus provide a gating influence over the information 
flow from the prefrontal cortex at the level of the NAc. Furthermore, among 
the multiple limbic regions that regulate PPI (Swerdlow et al., 2001), the 
hippocampus and the amygdala were found to contribute to the sensorimotor 
gaiting deficit produced by NMDA antagonists (Bakshi and Geyer, 1998). On the 
other hand, NAc is considered as a pivotal structure in regulating the locomotor-
activating effects (de Leonibus et al., 2001) whereas PFC plays a vital role in 
working memory deficit evoked by these drugs (Verma and Moghaddam, 1996). 
Taken together it can be argued that the inverse c-fos expression observed in the 
hippocampus and the CeA might indicate a dose-dependent ketamine-evoked 
deficit in the hippocampal and amygdala gating mechanism on the information 
flow between the PFC and Nac, which contributes to the profound effects of 
the highest doses of ketamine on the locomotion as well as on the cognitive 
function. 
 In conclusion, at a dose range of 4-16 mg/kg ketamine induced 
hyperlocomotion in a dose dependent manner and this was not influenced by the 
dark/light cycle. Ketamine also produced dose-dependent sensorimotor gating 
deficit with a maximal reduction in PPI manifested as PPF at the dose 8 and 
12 mg/kg. In addition, 12 mg/kg ketamine impaired working memory deficit 
assessed by discrete-trial delayed alternation test.  As c-fos expression indicated, 
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ketamine increased cell activity in cortical areas, NAc and the hypothalamus 
irrespectively of dosage while in the hippocampus and amygdala an inverse 
dose-dependent c-fos induction was observed. These latter finding might indicate 
that systemic ketamine dose dependently interrupts the neurotransmission within 
these two structures and, as a consequence, disrupts the information flow between 
other interconnected limbic regions such as PFC and NAc, which in turn lead to 
a profound behavioural effects evoked by higher dosages. 
3
Subchronic administration of LY354740 does not modify 
ketamine-evoked behaviour and neuronal activity in rats
Gabor Imre, Dirk S. Fokkema, Gert J. Ter Horst.




Acute treatment with LY354740 {1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-
2,6-dicarboxylate monohydrate}, a potent and selective agonist for group II 
metabotropic glutamate receptors (mGlu2/3), has previously been shown to 
block some schizophrenia-like effects of N-methyl-D-aspartate (NMDA) recep-
tor antagonists, suggesting a novel therapeutic strategy for schizophrenia. The 
present study examined the effects of subchronic pretreatment with LY354740 
(0.3, 3 and 10 mg/kg i.p.) on ketamine-evoked (12 mg/kg s.c.) prepulse inhibi-
tion deficits, hyperlocomotion and c-fos expression. At all doses, LY354740 
failed to reverse both behavioural and neuronal effects of the ketamine. These 
results therefore do not support the putative antipsychotic role of LY354740. 
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INTRODUCTION
 LY354740 is a potent and selective agonist at the metabotropic glutamate 
2/3 receptors (mGlu2/3) without significant affinity for the other mGlu receptors 
or ionotropic glutamate receptors (Schoepp and Marek, 2002). Numerous 
electrophysiological and microdialysis studies have demonstrated that LY354740 
is able to suppress glutamatergic transmission in limbic synapses (Anwyl, 1999). 
Behaviourally, it exhibits potent anxiolytic-like effects without sedative effects 
or motor impairments (Helton et al., 1998). Furthermore, systemic LY354740 
has been shown to be active in the N-methyl-D-aspartate (NMDA) receptor 
hypofunction model of schizophrenia. Exposure to non-competitive NMDA 
receptor antagonists like phencyclidine (PCP), or its analogue ketamine, 
produces behavioural syndromes in healthy individuals that resemble both 
positive and negative symptoms of schizophrenia (Krystal et al., 1994). In 
rodents, these symptoms manifest as impaired prepulse inhibition, cognitive 
deficits and augmented locomotion (Jentsch and Roth, 1999). The behavioural 
effects of these drugs have been attributed primarily to the blockade of NMDA 
receptors located on γ-aminobutyric acid (GABA) interneurons, which in turn 
leads to disinhibition of neuronal activity in limbic structures (Moghaddam et 
al., 1997). Accordingly, microdialysis studies in conscious rats have indicated 
PCP- and ketamine-evoked increases in glutamate and dopamine outflow in the 
prefrontal cortex and limbic striatal regions (Lorrain et al., 2003a; Moghaddam 
et al., 1997).  
 Moghaddam and Adams (1998) showed that LY354740 attenuated the 
disruptive effect of PCP on working memory, stereotypy, locomotion and 
cortical glutamate efflux. Several lines of evidence extended this study showing 
that both LY354740, and the more potent mGlu2/3 receptor agonist LY379268, 
effectively block PCP- and ketamine-evoked motor impairments (Cartmell et 
al., 1999a; Lorrain et al., 2003b; Spooren et al., 2000a). These data indicate that 
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the activation of mGlu2/3 receptors may represent a novel non-dopaminergic 
therapeutic strategy for certain schizophrenia-related symptoms (Schoepp and 
Marek, 2002). Recent studies have, however, cast doubt on this hypothesis, 
as LY354740 failed to restore NMDA receptor antagonist-induced deficits in 
prepulse inhibition and cognitive function (Henry et al., 2002; Ossowska et al., 
2000; Schreiber et al., 2000). 
The aim of this study was to assess the proposed antipsychotic properties of 
LY354740. Since acute treatment with LY354740 gave ambiguous results in the 
NMDA receptor hypofunction model of schizophrenia, we used a subchronic 
treatment regime (8 days), with a dose range of 0.3-10 mg/kg (i.p.). Unlike 
PCP, ketamine is available for use in human giving the possibility to replicate 
animal studies in human. To this end, we investigated the effects of LY354740 
on ketamine-evoked prepulse inhibition deficits and hyperlocomotion. In order 
to establish the putative cerebral site of action of LY354740, c-fos expression 




Forty-six male Wistar rats (n=6/group) weighing 248±8 g at the start of the experiments were 
individually housed with a 12/12 h light/dark cycle (lights on at 7:00 a.m.). Food and water were 
available ad libitum. All animals were handled and weighed daily to minimise stress during the 
experiment. The Animal Ethics Committee of the University of Groningen approved the protocols 
(FDC: 2935).  
DRUGS
Ketamine (Sigma, Germany) and LY354740 {1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-
dicarboxylate monohydrate}(Eli Lilly and Company, Indianapolis) were dissolved in saline. 
Animals were injected with either saline or one of the three different doses of LY354740 (0.3, 3 
and 10 mg/kg) intraperitoneally (i.p.) for eight consecutive days. On the experimental days, 30 min 
after the daily injection, either saline or 12 mg/kg ketamine were applied subcutaneously (s.c.). 
The behavioural testing and the immunohistochemistry procedures were the same as those used in 
previous experiments.
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BEHAVIOURAL TESTS
Prepulse inhibition: studies were performed on the 6th day of the treatment using a TSE Startle 
Response Measuring System (Bad Homburg, Germany). Following subcutaneous injection, the 
rats were placed in the startle box for a 5-minute acclimatization period with a 70 dB background 
noise. This noise continued throughout the session. The test session consisted of four trial types: 
(1) rats were exposed to 120 dB, 40-ms startle pulse; (2) a 85 dB 20-ms prepulse preceded the 
startle pulse by 100 ms; (3) prepulse alone; (4) no-stimulus. One session consisted of 35 trials with 
3 consecutive startle pulse alone trials in the beginning and 32 subsequent trials (each of them 
8 times) presented in a random order, with range 10-20 s intertrial interval. Percentage prepulse 
inhibition was calculated as follows: 100-[100×(mean amplitude on prepulse trials/ mean amplitude 
on startle pulse alone trials)]. 
Open field: the rats were tested in an open field (circular black arena with a diameter of 1 m) on the 
7th day of the treatment. Rats were placed in the centre of the field at certain time points i.e. at 0, 20 
and 40 min post subcutaneous injection and observed for a period of 8 min. Behaviour was recorded 
with a videotracking system (Etho Vision, 3.0, Wageningen, The Netherlands). The distance moved 
within the arena was analysed.
IMMUNOHISTOCHEMISTRY
On the 8th day of the treatment the rats were terminated two hours after the subcutaneous injection, 
with an overdose of isoflurane preceding a transcardial perfusion with 4% paraformaldehyde 
solution dissolved in 1.0 M sodium phosphate buffer (pH 7.4). C-fos staining was performed on 
free-floating sections (40 µm) under continuous agitation.  C-fos positive cells in the area of interest 
were blindly quantified in a single focus plane, using a computerised image analysis system (Lecia 
Qwin version 2.3). The average of immunoreactive cells was expressed as number of positive 
nuclei/0.1 mm2.
STATISTICAL ANALYSIS
Statistical analyses were done with SPSS (version 12.0), and P<0.05 was considered significant. 
Locomotor activity was analyzed with repeated measures analysis of variance (ANOVA), with time 
(3 trials) being specified as within subject factor, pretreatment and treatment as between subject 
factor. Sphericity assumed modelling, with Huynh-Feldt adjustment, was applied. C-fos and 
prepulse inhibition were analyzed with two-way ANOVA with pretreatment treatment as between 
subject factors. An LSD post hoc test was used for the pairwise comparisons. 
RESULTS
PREPULSE INHIBITION
Ketamine reduced prepulse inhibition (decrease of ~ 70%, Fig. 1A) in the 
saline pretreated group (F (1, 39) =39.086, P<0.001) and the startle reflex 
magnitude (F (1, 39) =13.089, P<0.001). Subchronic pretreatment with different 
dosages of LY354740 failed to restore this ketamine-evoked prepulse inhibition 
deficits (pretreatment×treatment interaction; F (3, 39) =1.601, P<0.205) and 
reduction in startle magnitude (F (3, 39) = 0.298, P<0.827). LY354740 on its own 
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had no main effect neither on prepulse inhibition (F (3, 39) =0.560, P<0.644) nor 
on startle magnitude (F (3, 39) =0.673, P<0.574).
Figure 1. Effect of pretreatment with mGlu2/3 receptor agonist LY354740 (0.3-10 mg/kg i.p.) 
in the prepulse inhibition paradigm (A) and the open field test (B). LY354740 did not restore the 
ketamine-evoked reduction in prepulse inhibition and startle magnitude. Similarly, LY354740 
could not prevent the ketamine-induced hyperlocomotion represented as total distance moved (cm). 
Pretreatment with LY354740 alone had no effect on prepulse inhibition and baseline locomotor 
activity. The * indicates P<0.05 treatment effect versus control.
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 OPEN FIELD
Overall ANOVA revealed a main effect of treatment (F (1, 39) =77.921, 
P<0.001) and treatment×time interaction (F (2, 32) =32.874, P<0.001). All 
groups receiving ketamine showed hyperlocomotion (increase of ~ 100% in the 
baseline activity) in the first (t=0, P<0.001) and second trial (t=20, P<0.05), which 
returned to control level 40 min after the injection (Fig. 1B). There was no main 
effect of pretreatment (F (3, 39) =1.707, P<0.181) and pretreatment×treatment 
interaction (F (3, 39) =1.118, P<0.353). LY354740 had no effect on both baseline 
and ketamine-evoked locomotion. 
IMMUNOHISTOCHEMISTRY 
Table 1 provides an overview of the data obtained from c-fos analysis of 
various regions. In general, pretreatment with LY354740 alone did not alter 
the c-fos expression compared to control. In the dentate gyrus and the CA1 
subregion of the hippocampus however, the numbers of c-fos positive cells were 
significantly lower in the LY354740- treated groups (dentate gyrus; F (3, 37) 
=2.882, P<0.049 and CA1; F (3, 37) =3.800, P<0.018). 
 With the exception the caudoputamen and the dorsomedial nucleus of the 
hypothalamus, two-way ANOVA revealed main effect of ketamine on the c-fos 
expression: in the cortical areas, the amygdala, the nucleus accumbens, CA1-
CA3 subregions of hippocampus, ventral tegmental area and the paraventricular 
nucleus of the hypothalamus significantly higher number of c-fos labeled cells 
were found, whereas in the dentate gyrus ketamine decreased the c-fos expression 
(F (1, 37) =22.640, P<0.001) compared to control. 
  Subchronic administration of LY354740 could not prevent the 
ketamine-induced c-fos expression. Although there was no significant 
pretreatment×treatment interaction, in the CA1-CA3 subregion of hippocampus 
as well as in the nucleus accumbens core the ketamine-induced c-fos expression 
was no longer significant at the dose of 3 and 10 mg/kg LY354740.
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Table 1. Regional c-fos expression following LY354740 pretreatment and ketamine/saline 
treatment. Mean number of c-fos positive cell per 0.1 mm2 ± SEM.
aP<0.05; bP<0.01; cP<0.001; significant changes in c-fos expression compared to control (s+s).
Two-way ANOVA followed by LSD post hoc test for pairwise comparison.
DISCUSSION 
The primary interest of this study was to evaluate the proposed antipsychotic 
action of the mGlu2/3 receptor agonist LY354740 in terms of the ketamine model 
of schizophrenia. Our study is in agreement with previous reports (Ossowska et 
al., 2000; Schreiber et al., 2000) insofar as we did not observe that subchronic 
pretreatment with LY354740 prevents the prepulse inhibition-disruptive effects 
of ketamine. Similarly, under the conditions of the present experiment, LY354740 
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also failed to restore ketamine-evoked hyperlocomotion and c-fos induction in 
many brain regions investigated. 
 The overall increase in c-fos expression (or decrease, in the case of 
dentate gyrus) shown in this study and previous microdialysis studies indicate 
that systemic ketamine can affect multiple brain sites involving several 
neurotransmitter systems. The resulting disturbances eventually culminate in 
the marked behavioural effects of ketamine. For instance, ketamine and other 
NMDA receptor antagonists selectively activate dopamine release in the nucleus 
accumbens and  prefrontal cortex of rats which is associated with hyperlocomotion 
and cognitive deficits (Jentsch and Roth, 1999). These effects could be prevented 
by administration of AMPA/Kainate receptor antagonists systemically or locally 
into the ventral tegmental area, primarily source of dopaminergic afferents to 
the prefrontal cortex and nucleus accumbens (Moghaddam et al., 1997; Mathe 
et al., 1998). Thus, dopamine release is thought to be secondary to increased 
glutamatergic neurotransmission at non-NMDA receptors. This concept is not, 
however, supported by a recent studies (Moghaddam and Adams 1998; Lorrain 
et al., 2003a) in which systemic administration of a mGlu2/3 receptor agonists 
was shown to prevent the NMDA receptor antagonists-induced augmentation in 
cortical glutamate release without blocking the increase in cortical dopamine 
efflux. Ketamine may also have direct agonistic effects on dopamine D
2
 receptor 
(Kapur and Seeman, 2002). Collectively, these data indicate that ketamine and 
other NMDA receptor antagonists can have an impact on the dopamine system 
that may be independent from glutamatergic mechanism, therefore it cannot be 
prevented by activation of mGlu2/3 receptors.
In addition to influencing glutamate and dopamine neurotransmission, 
ketamine and other NMDA receptor antagonists can increase serotonin and 
noradrenaline release in brain regions that mediate prepulse inhibition, such 
as prefrontal cortex, nucleus accumbens and hippocampus (Moghaddam et 
al., 1997; Lindenfors et al., 1997; Lorrain et al., 2003b). Accordingly, atypical 
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-adrenergic receptors contributes to the efficiency of these drugs, 
since the highly selective 5-HT
2A
 receptor antagonist M100907 and α1-adrenergic 
receptor antagonist prazosin, but not the D
2
 receptor antagonist haloperidol, 
is effective in this model (Geyer et al., 2001). This may help to explain the 
ineffectiveness of the highly selective mGlu2/3 receptor agonist LY354740 in the 
present study: the drug may not have effectively countered all the wide-ranging 
neuropharmacological effects of ketamine. On the other hand, we cannot rule 
out the possibility that tolerance developed to the ability of LY354740 to counter 
ketamine-induced deficits (Galici et al., 2005).   
In the present experiment, LY354740 had no measurable effect on animals’ 
spontaneous activity and it did not alter c-fos expression in most of the area 
investigated. This result is in line with the hypothesis that, under non-pathological 
neuropharmacological conditions, mGlu2/3 receptors play no role in modulation 
of neurotransmission (Scanziani et al., 1997). In the dentate gyrus and CA1, 
however, we observed reduced basal c-fos expression following LY354740 
pretreatment. Group II mGlu receptors have been found with the highest densities 
in the terminal fields of the perforant path projection from the entorhinal cortex 
to CA1 stratum lacunosum moleculare and the mid-molecular layer of the 
dentate gyrus (Petralia et al., 1996; Shigemoto et al., 1997). Therefore, it is 
conceivable that these areas are sensitive for the pretreatment with LY354740. 
In fact, the anxiolytic effects of this compound have been associated with 
suppressed hippocampal neurotransmission (Linden et al., 2004; Tatarczynska 
et al., 2001). Under normal conditions, LY354740 also produces cognitive 
impairment by its inhibitory effect on hippocampal synaptic transmission 
(Higgins et al., 2004). On the other hand, LY354740 has been shown to improve 
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PCP-evoked working memory deficit by blocking increased glutamate release 
in the prefrontal cortex (Moghadam and Adams, 1998). Although our results do 
not support the antipsychotic properties of LY354740, in future studies it will be 
important to examine the possible relationship between the effects of LY354740 
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One of the functions of group II metabotropic glutamate receptors (mGlu2/3) is 
to modulate glutamate release. Thus, targeting mGlu2/3 receptors might be a 
novel treatment for several psychiatric disorders associated with inappropriate 
glutamatergic neurotransmission, such as schizophrenia. In an effort to evalu-
ate the antipsychotic properties of LY379268, a potent and selective mGlu2/3 
receptor agonist, we examined its effect on ketamine-evoked hyperlocomotion 
and sensorimotor gating deficit (PPI) in rats, an animal model of schizophrenia. 
We also measured the ex vivo tissue level of glutamate (Glu), dopamine (DA) 
and serotonin (5-HT) as well as the DA metabolites DOPAC and the major 
5-HT metabolite HIAA to determine the neurochemical effects of ketamine (12 
mg/kg) and LY379268 (1 mg/kg) in the dentate gyrus (DG). While LY379268 
(1-3 mg/kg) reduced ketamine-evoked hyperlocomotion (12 mg/kg), it could 
not restore ketamine-evoked PPI deficits (4-12 mg/kg). In the DG we found that 
ketamine decreased Glu and DA levels, as well as HIAA/5-HT turnover, and that 
LY379268 could prevent ketamine effects on Glu level but not on monoamine 
transmission. These results may indicate that the inability of LY379268 to re-
verse PPI deficits is attributable to its lack of effect on ketamine-induced chang-
es in monoamine transmission, but that LY379268 can prevent ketamine-evoked 
changes in glutamate, which is sufficient to block hyperlocomotion. In addition 
to the partial effectiveness of LY379268 in the ketamine model of schizophrenia, 
we observed a dual effect of LY379268 on anxious states, whereby a low dose 
of this compound (1 mg/kg) produced anxiolytic effects, while a higher dose (3 
mg/kg) appeared to be anxiogenic. Additional work is needed to address a pos-
sible role of LY379268 in schizophrenia and anxiety treatment. 
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INTRODUCTION
Glutamate, as the major excitatory neurotransmitter in the mammalian central 
nervous system, plays a role in many brain processes including sensory and motor 
function, cognition and regulation of perception and emotion (Meldrum, 2000). 
Consequently, abnormal changes in glutamatergic neurotransmission can lead 
to a neuronal dysfunction, resulting in a variety of neurological and psychiatric 
disorders, such as anxiety and schizophrenia (Chavez-Noriega et al., 2002). In the 
search of novel treatment for these disorders, the members of group II metabotropic 
glutamate receptors (mGlu2/3) have emerged as potential therapeutic targets. 
Activation of the mGlu2/3 receptors provide a negative feedback mechanism 
to prevent excessive presynaptic glutamate release in limbic regions that have 
been implicated in pathology of affective disorders (Chavez-Noriega et al., 
2002; Schoepp and Marek, 2002). In particular, the potent, selective mGlu2/3 
receptor agonist, LY354740 has been shown to have anxiolytic-like activity in 
several animal models of anxiety, including fear-potentiated startle, the elevated 
plus-maze and the conflict drinking test (Helton et al., 1998; Klodzinska et al., 
1999; Linden et al., 2004). Furthermore, LY354740 and its more potent analogue, 
LY379268, have been shown to be active in the NMDA receptor hypofunction 
model of schizophrenia.
 Non-competitive NMDA receptor antagonists, such as phencyclidine (PCP) 
or its analogue ketamine, administered to healthy individuals produce symptoms 
common in schizophrenia (Javitt and Zukin, 1991; Krystal et al., 1994) and 
have been used in rodents to model behavioural abnormalities associated with 
schizophrenia, including disruption in the prepulse inhibition of startle reflex (PPI), 
working memory deficits and augmented locomotion (Aultman and Moghaddam, 
2001; Lorrain et al., 2003b; Mansbach and Geyer, 1991). The adverse behavioural 
effects of these drugs have been attributed primarily to blockade of NMDA 
receptors on inhibitory GABAergic neurons, which in turn leads to release of 
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various neurotransmitters including glutamate (Glu), dopamine (DA), serotonin 
(5-HT) and noradrenaline (NE) in forebrain regions (Lindefors et al., 1997; 
Lorrain et al., 2003a-b;  Moghaddam et al., 1997). Among these responses, recent 
findings have highlighted the importance of glutamate neurotransmission: both 
LY354740 and LY379268 blocked NMDA antagonists-evoked glutamate release 
in the prefrontal cortex (PFC) and nucleus accumbens, attenuating the disruptive 
effects on locomotion and working memory (Moghaddam and Adams, 1998). 
Furthermore, LY379268 shares common neurochemical characteristics with 
clozapine-like atypical antipsychotics that are generally effective in this model 
due to their multiple antagonist properties (Geyer and Ellenbroek, 2003). Similar 
to clozapine and risperidone, LY379268 increased the turnover of dopamine 
and 5-HT in the PFC and striatum, as measured by in vivo microdialysis and ex 
vivo tissue destruction (Cartmell et al., 2000b-c, 2001). These studies imply that 
modulation of excitatory neurotransmission via mGlu2/3 receptors may represent 
a novel approach to treat schizophrenia. 
However, recent reports did not support this hypothesis, since LY354740 failed 
to reverse the disruption of prepulse inhibition induced by NMDA antagonists, 
nor did it restore cognitive dysfunction (Ossowska et al., 2000; Schreiber et 
al., 2000). Moreover, studies from this laboratory showed that subchronic 
pretreatment with LY354740 did not prevent ketamine–evoked hyperlocomotion 
and PPI deficits. 
 Because of these contradictory results with LY354740, the primary aim of 
this study was to explore the potential of a related mGlu2/3 receptor agonist as 
a novel antipsychotic, using the ketamine model of schizophrenia. Therefore, 
we investigated the ability of LY379268 to suppress ketamine-evoked 
hyperlocomotion and PPI deficits.  To our knowledge, this is the first study that 
reports on the effects of LY379268 on sensorimotor gating deficits.
We also investigated the neurochemical effects of ketamine and LY379268 
treatment on neurotransmission in the dentate gyrus (DG). This subregion of the 
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hippocampus has raised particular interest for three reasons. First, aside from 
the PFC and amygdala, the hippocampus has been shown to mediate the PPI 
disruptive actions of NMDA antagonists (Bakshi and Geyer, 1998). Second, both 
NMDA and mGlu2/3 receptors are abundant in the DG (Petralia et al., 1994, 
1996). Third, our c-fos data have indicated that both ketamine and LY354740 
decrease cell activity within this region and this reduction was more profound 
when the two drugs were administered together. Such a synergistic effect was 
not observed in other brain areas investigated. To this end, we examined the ex 
vivo tissue levels of glutamate and monoamines in the DG following treatment 
with ketamine and LY379268. We also measured the level of the DA metabolite 
3, 4- dihydroxyphenylacetic acid (DOPAC), as well as the 5-HT metabolite 5-
hydroxyindoleacetic acid (5-HIAA), in order to calculate the tissue DOPAC:DA, 
and 5-HIAA:5-HT ratios, which are considered to be indications for drug-induced 
changes in neurotransmitter utilization across different brain regions.
MATERIALS AND METHODS
ANIMALS 
Fifty-four adult male Wistar rats weighing 200-250 g at the beginning of the experiments were 
individually housed and maintained on a 12 h light/dark cycle with the light cycle beginning at 7.00 
a.m. Food and water were available ad libitum (standard rat chow). All animals were handled and 
weighed daily to minimise stress during the experiments. The Animals Ethics Committee of the 
University of Groningen approved all protocols (DEC 2935). 
DRUGS
 Ketamine (Sigma, Germany) and LY379268 (-)-2-oxa-4-aminobicyclo [3.1.0] echane – 4, 6- 
dicarboxylic acid (Eli Lilly and Company, Indianapolis) were dissolved in saline. In order to 
perfectly dissolve LY379268 in saline, 1 µl of 5N NaOH was added for every mg of LY379268 
(~pH6) and placed in a bath sonicator for a short time. All solutions were freshly prepared before 
injection. Animals were injected with LY379268 (1-3 mg/kg) intraperitoneally (i.p.) 30 min prior 
to test, while ketamine (4-12 mg/kg) was applied subcutaneously (s.c.) immediately before the 
start of behavioural tests.  A 7-day interval was allowed between each experiment. Following each 
behavioural test the animals were divided into groups (n=6/group) in a way that each new group 
was balanced, containing 1 animal from every former group.
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OPEN FIELD TEST (OF)
The behavioural effects of the drug treatments were tested in an open field that consisted of a 
circular black arena with a diameter of 1 m bordered by 40-cm high walls. The testing room was 
illuminated with 3 25-W bulbs placed around the open field. Immediately following the second 
injection (12 mg/kg ketamine or saline), rats were placed in the centre of the open field (trial 1; 
t=0) for a period of 5 min and this test was repeated 20 (t=20), 40 (t=40), 60 (t=60) and 90 (t=90) 
min after the second injection. The test was performed in the light period between 8 a.m. and 12 
a.m. Locomotor behaviour was recorded with a video tracking system (Etho Vision 3.0. Noldus 
Information Techonology, Wageningen, The Netherlands). Rearing behaviour was manually 
recorded. Locomotor and exploratory behaviour were expressed as total distance moved and 
rearing duration respectively.
PREPULSE INHIBITION OF THE STARTLE REFLEX (PPI)
One week after the OF tests, the PPI test was performed using a TSE Startle Response Measuring 
System. The rats were locked in a small cage (270×100×125 mm) restricting major movements and 
exploratory behaviour and were placed on a transducer platform. Acoustic stimuli were generated 
by means of high-quality high-linearity speakers situated on both sides of the cage. The complete 
set-up was operated in a sound-attenuating isolation chamber equipped with a ventilation fan and 
house light. 
We tested the effect of different doses of LY379268 (1 and 3 mg/kg) alone or in combination with 
12 mg/kg ketamine. Since this dose of ketamine was two-fold higher than a dose necessary to 
induce PPI deficits, we also examined the effect of 1 mg/kg LY379268 on PPI deficits evoked by 
low doses of ketamine (4 and 8 mg/kg). Immediately after the second (ketamine or saline) injection, 
the rats were placed in the startle box for a 5 min acclimatisation period with a 70 dB background 
noise. This noise continued throughout the session. 
The sessions consisted of four types of trials and were given 8 times in a random order: (1) 
prepulse (PP) alone:  85 dB sound for 20 ms; (2) startle pulse (SP) alone: 120 dB sound for 40 ms; 
(3) prepulse + startle pulse (PP+SP): 85 dB prepulse for 20 ms followed 100 ms later by 120 dB 
sound; (4) nothing: 70 dB background noise. One session consisted of 35 trials and lasted ~ 9 min, 
with 3 consecutive SP alone trials in the beginning and 32 subsequent trials (each of them 8 times) 
presented in a random order, with 15-s average (range 10-20 s) intertrial interval.
PPI was defined as the percentage reduction in mean startle response magnitude (SRM) in the 
presence of the prepulse compared to mean SRM in the absence of the prepulse: 100-[100×(mean 
SRM PP+SP trials/mean SRM SP alone trials)]. The first three SP alone trials, which were 
presented at the beginning of the test session, were not included in the calculation of the PPI values. 
Since these first pulses are necessary to achieve a relatively stable level of startle reactivity for the 
remainder of the session (based on the observation that the most rapid habituation of the startle 
reflex occurs within the first few presentations of the startling stimulus {Geyer et al., 1990}). 
BIOCHEMISTRY
One week after the PPI tests, 24 non-naïve rats were terminated to assess neurotransmitter level 
using HPLC analysis. In addition, an extra group of drug-naïve rats (n=6, same age and weight 
as non-naïve rats) were included in order to examine the possible carry-over effects of the drug 
treatments.  These “blank” controls did not receive any injection while the non-naïve rats underwent 
the same injection procedure as for the behavioural tests. Thirty min after the last injection (12 
mg/kg ketamine or saline), rats were anaesthetised with 5% isoflurane and decapitated; brains 
were quickly removed and frozen in -80°C and trunk blood was collected for corticosterone radio 
immuno-assay (RIA).
Serial 300 µm coronal sections were made with a cryostat microtome (-15°C) and kept frozen 
on dry ice. Tissue samples were dissected from the dentate gyrus (DG: bregma -2.45 to -3.70; 
{Swanson, 1992}) by using a needle punch technique (16GA11⁄2; 1,6×40, inner diameter: 1 mm, 
BD Microlance). Four punches per animal were taken (one punch ~ 0, 23 mm³) and diluted in 100 
µl 0.1 M HCLO
4.
 Brain tissue was pulverised and then centrifuged (13.500 rpm for 10 min), the 
supernatant was analysed by HPLC with electrochemical and fluorescence detection. 
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Analysis of dopamine (DA), 3,4-dihyroxyphenylacetic acid (DOPAC), hydroxyindoleactic acid 
(HIAA), serotonin (5-HT) and noradrenaline (NE) was performed by a Shimadzu LC-10 AD high 
performance liquid chromatograph equipped with a 15-cm reversed phase column (supelcosil 3 µm, 
C18, 150×4.60 mm, Bester, Amstelveen, The Netherlands) and an electrochemical detector (ESA, 
Chelmsford, MA, USA) at a potential setting of 300 mV. The mobile phase consisted of 10% 
MeOH, 4.2 g Na Acetate/L, 150 mg OSA (octane sulphonic acid)/L adjusted to pH 4.10. The 
injection volume was 20 μl and the flow rate 1 mL/min. 
Analysis of Glutamate was performed after derivatisation with OPA (ortho-phtaldehyde) by a 
Shimadzu LC-10 AD high performance liquid chromatograph equipped with a 15-cm reversed 
phase column (supelcosil 3 µm, C18, 150×4.60 mm, Bester, Amstelveen, The Netherlands) and a 
fluorescence detector (Waters 470, fluorescence detection, Waters, Milford, Massachusetts, USA) 
with λ
ex
 set at 350 nm and λ
em 
set at 450 nm. The mobile phase consisted of 26% MeOH, 10 g/L 
disodiumphosphate (Na2HPO4), 150 mg/L EDTA, 2.19 ml/L THF (tetrahydrofuran) adjusted to pH 
5.27. The injection volume was 20 μl and the flow rate 1 mL/min. 
CORTICOSTERONE RADIO IMMUNO-ASSAY
The corticosterone fraction was extracted from the plasma (10 µl) with Chromosorb (Alttech) and 
30% dichloromethane (Rathburn 1001). Before the extraction a trace amount of 3H labelled (200 
Bq) corticosterone (TRK-406 Amersham) was added to the samples to determine recovery which 
was 20%. A standard curve was determined by using non-labelled corticosterone, which was treated 
in the same way as the extracted plasma samples. 
For the quantification, samples were mixed with 3H (500 Bq) labelled corticosterone and polyclonal 
antibody raised against corticosterone (rabbit nr 568 UMCG). Tubes were incubated at 60°C for 
30 min and the equilibrium reaction was established in a water/ice bath for 1 h. The reaction was 
stopped by adding charcoal suspension and incubated for 15 min in the water/ice bath. Tubes were 
centrifuged for 15 min at 3000*g and 4°C to spin down the charcoal bound with free corticosterone. 
The supernatant was poured into 1 ml of scintillation fluid (Ultimagold XR, Canberra Packard) and 
samples were counted in a β-counter for 4 min or 4000 presetcounts. The amount of corticosterone 
was calculated from the standard curve.
STATISTICAL ANALYSIS
Data are presented as mean ± SEM. Statistical analyses were done with SPSS (version 12.0), and 
P<0.05 was considered significant. Locomotor and exploratory behaviour were analysed by repeated 
measures ANOVA, with time (5 trials) as a within subject factor and pretreatment and treatment as 
between subject factors. Sphericity assumed modelling, with Huynh-Feldt adjustment, was applied. 
The PPI test and the HPLC results were analysed with two-way ANOVA with pretreatment and 
treatment as a between subject factor. A LSD post hoc test was used for pair-wise comparisons.
RESULTS
OPEN FIELD TEST
As repeated measures ANOVA revealed, pretreatment had a main effect on 
locomotor activity (F (3, 35) =39.040, P<0.001) and rearing (F (3, 35)
 
=24.711, 
P<0.001). At the doses of 2 and 3 mg/kg, LY379268 significantly decreased 
locomotion in each trial (t=0, 20, 40 and 60, P<0.001 and t=90, P<0.05; Fig. 
1). Subjectively, some side effects were noted: animals displayed freezing 
Chapter 4
68
behaviour, urinated frequently and appeared to be hypersensitive to tactile 
stimuli. Accordingly, the exploratory behaviour of the rats was abolished by 
treatment with 2 and 3 mg/kg of LY379268, as time spent rearing illustrates (Fig. 
3). Animals treated with 1 mg/kg LY379268 revealed no gross abnormalities, 
although they appeared to be less active, as shown by the non-significant decrease 
in total distance moved (Fig. 1) and significantly decreased rearing behaviour 
(P<0.05; Fig. 3). 
As expected, within two minutes after its administration, ketamine induced (F 
(1, 35) =21.840, P<0.001; Fig. 2) hyperlocomotion which remained significantly 
elevated in the first two trials (t=0, P<0.001 and t=20, P=0.020). In addition, 
ketamine abolished rearing behaviour in the first three trials (t=0 and t=20, 
P<0.001; t=40, P<0.05; Fig. 3). 
There was a main effect of time (P<0.001), time×treatment interaction 
(P<0.001) and time×pretreatment×treatment interaction (P<0.001). Although test 
of between subject effects showed no pretreatment×treatment interaction (F (2, 
35)
 
=2.389, P=0.109), administration of 1 and 3 mg/kg of LY379268 suppressed 
the ketamine-evoked hyperlocomotion (Fig. 2). It should be noted that animals 
treated with 3 mg/kg of LY379268 together with ketamine still displayed the 
above-mentioned side effects evoked by LY379268. The dose of 1 mg/kg 
LY379268 significantly reduced the ketamine-evoked hyperlocomotion (t=0 and 
t=20, P<0.05; Fig. 2) without any side effects. None of the doses of LY379268 
could restore the ketamine effect on rearing behaviour (Fig. 3).
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Figure 1. Effect of LY379268 per se (dose range 1-3 mg/kg) on locomotion represented as total 
distance moved. All doses of LY379268 decreased locomotion compared to the control in all 
five trials but this effect was significant at the dose of 2 and 3 mg/kg LY379268. Figure 1A-C: 
characteristic walking pattern of control (A),1 mg/kg LY379268 (B) and 2-3 mg/kg LY379268 
treated (C) rats in the open field arena during the first trial (t=0). Points represent the mean ± S.E.M. 
for n=6 rats/trial. The * indicates P<0.05 at dose of 2 and 3 mg/kg LY379268 versus control.
Figure 2. Effect of LY379268 (1-3 mg/kg) on ketamine-evoked hyperlocomotion (12 mg/kg) 
represented as total distance moved. Figure 2A-C: characteristic walking pattern in the open 
field arena during the first trial (t=0). Consistent with a short-lasting effect, ketamine significantly 
increased locomotion (A) in the first two trials. Pretreatment with 1 (B) and 3 mg/kg (C) of 
LY379268 was able to prevent this effect of ketamine. Points represent the mean ± S.E.M. for n=6 
rats/trial. The * indicates P<0.001 for ketamine versus control.
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Figure 3. Effect of 
pretreatment with 
LY379268 (1 and 3 mg/kg) 
on exploratory behaviour 
represented as time spent 
rearing. Ketamine caused 
a significant decrease in 
rearing duration in the 
first three trials (t=0 and 
t=20, P<0.001; t=40, 
P<0.05). LY379268 (1 
mg/kg) was not able to 
prevent this ketamine 
effect. When administered 
alone, LY379268 dose-
dependently decreased 
rearing behaviour. Data 
expressed as mean ± S.E.M 
for n=6 rats/trial.
PREPULSE INHIBITION
Univariate ANOVA showed a significant ketamine main effect on PPI (F (2, 
28) =3.935, P<0.05). As the negative PPI value represented (Fig. 4) 12 mg/kg 
ketamine induced prepulse facilitation (PPF; the startle amplitude in PP+SP trials 
was larger than in SP alone trials). Pre-treatment with LY379268 (1 and 3 mg/kg) 
was not able to restore the ketamine-evoked PPI deficit. Although there was no 
pretreatment×treatment interaction (F (2, 28) =1,196, P=0.319), the compound 
appeared to exacerbate dose-dependently this symptom of ketamine. None of 
the doses of LY379268 per se altered PPI compared to the control group (F (2, 
28) =2.2821, P=0.077). However, administration of the highest dose (3 mg/kg) 
alone increased the startle reflex magnitude fivefold (F (2, 28) =11.633, P<0.001). 
Interestingly, this effect of 3 mg/kg LY379268 was reduced by ketamine 
(pretreatment×treatment interaction, F (2, 28) =9.735, P<0.001; Fig. 4).
Our preliminary dose-response studies demonstrated that ketamine is able 
to induce maximal PPI deficits at the dose of 4 and 8 mg/kg (data not shown). 
Pretreatment with 1 mg/kg LY379268 could not prevent the PPI deficit evoked by 
the lower doses of ketamine (Fig. 5).
LY379268 and the ketamine model
71
Figure 4. Effect of pretreatment with LY379268 (1 and 3 mg/kg) on prepulse inhibition (PPI) 
and startle reflex magnitude (SRM). LY379268 on its own did not alter PPI. Administration of 12 
mg/kg ketamine significantly disrupted PPI, resulting in prepulse facilitation (PPF). Pretreatment 
with LY379268 did not prevent this ketamine effect but did tend to exacerbate it dose-dependently. 
Treatment with ketamine (12 mg/kg) caused a slight tendency towards a decrease in SRM. 
Treatment with 1 mg/kg LY379268 has no effect on its own while 3 mg/kg LY379268 per se 
significantly increased SRM (Inset). Interestingly, the combination of the two drugs did not alter 
SRM. Data expressed as mean ± S.E.M for n=6 rats. The * indicates P<0.05 vs control.
Figure 5. Effect of 
pretreatment with LY379268 
(1 mg/kg) on PPI deficits 
evoked by different doses 
of ketamine. Irrespective of 
the dosage of ketamine, 1 
mg/kg LY379268 could not 
prevent the disruptive effect 
of ketamine on PPI. Data 
expressed as mean ± S.E.M 




PLASMA CORTICOSTERONE LEVEL 
As Table 1 illustrates, there was no difference in plasma corticosterone level 
between drug-naïve and non-naïve control groups. Ketamine significantly 
increased the plasma corticosterone level (tenfold higher compared to 
control; F (1, 20) =555.989, P<0.001), which was unaffected by LY379268 
(pretreatment×treatment interaction, F (1, 20) =1.104, P=0.306). Pretreatment 
with 1 mg/kg LY379268 had no effect on baseline corticosterone level (F (2, 28) 
=0.79, P=0.781).  
Table 1 Effect of LY379268 (1 mg/kg) and ketamine (12 mg/kg) on plasma corticosterone level. 
Data are presented as mean ± S.E.M., *P<0.001 versus non-naïve control.
NEUROCHEMICAL RESULTS
 Table 2 provides an overview of the data obtained from HPLC analysis 
of dentate gyrus (DG). Comparison of drug-naïve animals (blank control) 
and non-naïve animals (saline-treated control) showed no differences in any 
neurotransmitter levels. Thus, for indication of drug treatment induced changes 
in the tissue content of neurotransmitters saline-treated, animals were used as 
control group.
 Ketamine significantly decreased tissue glutamate levels (F (1, 20) =5.535, 
P<0.032), which was restored by LY379268 (pretreatment×treatment interaction, 
F (1, 20) =4.282, P<0.05). LY379268 alone had no effect on glutamate (F (1, 
20) =0.552, P<0.446). A significant reduction of dopamine concentration was 
observed following treatment with ketamine (F (1, 17) =5.474, P<0.035). 
LY379268 could not prevent this ketamine effect (pretreatment×treatment 
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own (F (1, 17) =1.684, P<0.215). 
 There was a ketamine main effect on HIAA level (F (1, 17) =7.572, P<0.014) 
and HIAA/5-HT turnover (F (1, 17) =10.124, P<0.005).  Pretreatment with 
LY379268 could not prevent these ketamine effects and it had no effect on its 
own. No changes were found in the tissue levels of noradrenaline, 5-HT and 
DOPAC, as well as in DOPAC/dopamine ratio. However, it should be noted that 
3 samples of LY379268+ketamine treated group were excluded from the DOPAC 
analysis due to a technical failure. 
Table 2. Ex vivo brain tissue concentration of neurotransmitters in the dentate gyrus: DA, DOPAC, 
5-HT, HIAA, noradrenaline (ng/sample ± S.E.M.) and glutamate (µg/sample ± S.E.M.), DOPAC/
DA ratio HIAA /5-HT ratio (mean ± S.E.M.). *P<0.05 vs non-naïve control.
DISCUSSION
The reversal effects of LY379268 on NMDA-antagonist-related motor 
impairments have been well characterized (Cartmell et al., 1999a-b; Lorrain et 
al., 2003b) and our findings replicated these previous reports, as LY379268 (1-3 
mg/kg) suppressed ketamine-evoked hyperlocomotion. However, administration 
of higher doses produced anxiogenic-like side effects. Animals treated with 2 
and 3 mg/kg of LY379268, alone or in combination with ketamine, exhibited 
freezing behaviour that was accompanied by frequent defecation and urination. 
Furthermore, at the dose 3 mg/kg LY379268 a ~5 fold increase in the startle reflex 
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(Koch, 1999). Similar anxiogenic-like effects have usually been observed at 
higher doses of LY379268 (10-100 mg/kg), resulting in ataxia to which tolerance 
developed following repeated administration, whereas the ability to block 
PCP-induced hyperlocomotion was retained (Cartmell et al., 2000a). Cartmell 
et al. also reported that although 3 mg/kg LY379268 reduced basal levels of 
locomotion, it did not produce motor impairment as measured on the rotorod 
apparatus, but it blocked PCP-related motor behaviours. Similarly, in the present 
study 1 mg/kg of LY379268 suppressed ketamine-induced hyperlocomotion 
without producing side effects. When it was applied alone, animals were grossly 
normal, showing no changes in startle reflex and plasma corticosterone level, 
but showed reduced exploratory behaviours, as the decrease in locomotion and 
rearing behaviour indicated (Fig. 1 and 3). These results might be interpreted as a 
reduced response to novelty stress (i.e. open field) due to an anxiolytic-like action 
of LY379268 at a low dose. Certainly, there is evidence to suggest that group II 
receptor activation might be anxiolytic. Wide range of preclinical (Helton et al., 
1998; Klodzinska et al., 1999; Linden et al., 2004; Shekhar and Keim, 2000) and 
recent clinical findings (Grillon et al., 2003; Schoepp et al., 2003) have reported 
that LY354740, a close structural analogue of LY379268, could suppress anxiety-
related behaviour, while LY379268 has been shown to prevent immobilization-
stress evoked hyperlactinemia (Johnson and Chamberlain, 2002). However, 
further behavioural studies would be necessary to confirm possible anxiolytic 
properties of the LY379268 at a low dose range. 
To date, all available studies have characterized the antipsychotic effects 
of LY379268 on NMDA antagonist-evoked motor behaviours rather than PPI 
deficits. The loss of PPI, however, provides an operational measure for studying 
sensorimotor gating deficits across species and for predicting antipsychotic activity 
in novel compounds (Geyer et al., 2001). Only two studies have examined the 
role of mGlu2/3 receptors in PPI deficits using the less potent agonist LY354740 
which could not prevent PCP-induced PPI disruption (Ossowska et al., 2000; 
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Schreiber et al., 2000). Moreover, our previous results from this laboratory have 
also shown that subchronic treatment with LY354740 was ineffective in restoring 
ketamine-evoked PPI deficits. Consistent with these findings, we found here that 
LY379268 failed to oppose the PPI deficits evoked by ketamine at a dose range 
of 4-12 mg/kg. Taken together, these data indicate that the underlying mechanism 
for disruption of PPI by NMDA antagonists cannot be prevented by activation of 
mGlu2/3 receptors. 
 Recent in vivo microdialysis and ex vivo tissue destruction studies have 
indicated that LY379268 shares common biochemical effects with atypical 
antipsychotics, which are generally active in the NMDA hypofunction model. 
Similar to clozapine and risperidone, LY379268 increased the tissue turnover of 
DA and 5-HT in the PFC and in the striatum (Cartmell et al., 2000c). In contrast, 
in the present study, LY379268 (1 mg/kg) had no effect on DA turnover or 5-
HT turnover in the dentate gyrus. It is likely that methodological differences, 
including dose ranges, time course and tissue dissection technique, underlie this 
apparent discrepancy. 
Nevertheless, we demonstrated here that ketamine reduced the tissue level 
of glutamate, dopamine and HIAA, as well as 5-HT turnover. Pretreatment with 
LY379268 could only prevent the ketamine effect on glutamate without altering the 
basal glutamate concentration (Table 2). This is in line with in vivo microdialysis 
studies which have demonstrated that activation of group II mGlu receptors by 
LY379268 or LY354740 has no effect on basal glutamate levels in the PFC or 
nucleus accumbens, even though these drugs can suppress NMDA antagonist-
evoked glutamate (but not dopamine) release (Lorrain et al., 2003a; Moghaddam 
and Adams, 1998). Moghaddam and Adams (1998) also demonstrated that the 
reduction in PCP-induced glutamate efflux by LY354740 was accompanied 
with blockade of PCP-evoked hyperlocomotion and stereotypical behaviour. 
Accordingly, the present data showed that LY379268 prevents the effects of 
ketamine on locomotion and glutamate transmission in the DG, but not on PPI 
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and monoamine levels. Therefore, it is conceivable that blockade of ketamine 
and other NMDA antagonist-induced changes in glutamate neurotransmission 
can reverse hyperlocomotion, but that it is neither sufficient nor capable in 
restoring PPI deficits. This latter symptom may rather be linked to changes 
in monoamine transmission.  Previous reports do support such a relationship, 





clozapine, chlorpromazine, and ziprasidone appeared to be effective in reversing 
NMDA antagonist-induced PPI deficits (Mansbach et al., 2001; Swerdlow et 
al., 1998). In particular, antagonist action on 5-HT
2 
receptors contributes to the 
efficiency of these drugs, since the highly selective 5-HT
2A
 receptor antagonist 
M100907, but not the dopamine antagonist haloperidol, is effective in this model 
(Keith et al., 1991, Mansbach et al., 2001; Varty et al., 1999). 
  In summary, the potent and selective mGlu2/3 receptor agonist LY379268 
is partly effective in the NMDA hypofunction model of psychosis since it could 
block the hyperlocomotion but not the PPI deficits induced by ketamine. We also 
demonstrated that ketamine reduced glutamate, dopamine and 5-HT turnover in 
the DG and that LY379268 could only prevent the ketamine effect on glutamate 
transmission. Thus, it can be concluded that blockade of glutamate transmission 
by LY379268 is not sufficient to reverse PPI deficits evoked by ketamine. In 
future studies it will be important to examine the effect of LY379268 on cognitive 
symptoms in this model.
  A final, not completely marginal, observation of this study was that in a 
narrow dose range, LY379268 showed a dual action in the anxious states, as 3 
mg/kg evoked freezing behaviour and an increased startle reflex, while 1 mg/
kg decreased exploratory behaviours interpreted as anxiolytic effects. Since 
its analogue LY354740 was found to be effective in several animal models 
of anxiety and in clinical studies, it is conceivable that LY379268 might have 
similar properties. Additional work should address the possible role of mGlu2/3 
receptors and LY379268 in anxiety.
5
Anxiolytic-like effects of mGlu2/3 receptor agonists 
LY354740 and LY379268: 
comparison of male and female rats





LY354740 and LY379268 are potent and selective group II metabotropic gluta-
mate receptor (mGlu2/3) agonists with activity in models of psychiatric disor-
ders including anxiety and psychosis. Although gender differences in behaviour 
and responses to psychoactive drugs are well recognized, anxiolytic properties 
of LY354740 were established using only male subjects. Conversely, LY379268 
has not been tested yet in anxiety-related paradigm such as the elevated plus 
maze (EPM). Thus, the present work investigated the gender differences in the 
effects of LY354740 (3 mg/kg) and LY379268 (1 mg/kg) on traditional and fear-
potentiated EPM test. In the latter test, animals underwent an acute inescapable 
footshock (IS) procedure prior to the EPM test in order to enhance the anxiety-
related behaviour. In addition, the expression of CREB/pCREB in the dentate 
gyrus (DG) was analyzed by Western blotting.
None of the mGlu2/3 receptor agonists showed anxiolytic effects on the tradi-
tional EPM irrespectively of gender. Similar to diazepam (1.5 mg/kg), LY379268 
could restore IS-induced changes in both genders, while LY354740 was effec-
tive only in females. As the Western blot analysis of the DG demonstrated, the 
reversal effects of these compounds might be associated with a restored CREB 
level in males and an increased pCREB level in females. Altogether, these data 
further support the anxiolytic properties of mGlu2/3 receptor agonists. Addi-
tionally, we observed gender differences in behaviour, corticosterone levels and 
CREB/pCREB expression under control condition and following the footshock 
procedure reinforcing the use of both sexes in research of anxiety/stress-related 
disorders 
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INTRODUCTION
Glutamate as the main excitatory neurotransmitter plays an important 
role in most physiological and pathological processes of the central nervous 
system (CNS) (Watkins, 2000). Glutamate acts through ionotropic receptors 
(iGlu: NMDA, AMPA and kainate) and via metabotropic receptors (mGlu1-8). 
Great hopes that modulation of glutamate neurotransmission by iGlu receptor 
antagonists could be applied in the therapy of CNS disorders were hampered by 
the fact that these agents (mainly NMDA antagonists) produce undesirable side-
effects such as psychotic-like episodes, memory impairment and ataxia (Danysz 
et al., 1998). These shortcomings can generally be attributed to the ubiquitous 
expression of iGlu receptors throughout the brain and the direct influence of 
theses compounds on fast excitatory neurotransmission. In contrast, mGlu 
receptors have unique but overlapping distribution in brain regions with relevance 
for different psychiatric disorders, where they have a subtle modulatory effect on 
glutamatergic transmission. 
 Currently eight mGlu receptor subtypes are characterized and classified into 
three groups (I-III) based on their sequence homology and signal transduction 
mechanism. Pharmacologically, the most is known about the group II members 
(mGlu2/3). These receptors are negatively coupled to adenylyl cyclase as the 
principal transduction pathway. Presynaptically they function as autoreceptors 
and inhibit glutamate release (Conn and Pin, 1997). Activation of postsynaptic 
mGlu2/3 receptors can suppress neuronal excitability and plasticity via modulation 
of ion channels (e.g. potassium) and induction of long-term synaptic depression 
(Anwyl, 1999). Converging results from in situ mRNA hybridization and 
specific antibodies showed that mGlu2/3 receptors are localized predominantly 
in psychiatric disorders-related regions such as prefrontal cortex, hippocampus, 
amygdala, thalamus and striatum. Thus, activation of mGlu2/3 receptors may 
provide a new treatment approach for psychiatric disorders associated  with 
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inappropriate or excessive glutamate release.
 In particular, a growing body of evidence implicates the mGlu2/3 receptor 
agonist LY354740 as a potential anxiolytic (Swanson et al., 2005). LY354740, a 
structural analogue of glutamate and highly selective mGlu2/3 receptor agonist, 
was found to be anxiolytic in fear-potentiated startle and elevated plus maze 
tests in rats without sedative effects or motor impairments (Helton et al., 1998). 
Recently, this anxiolytic action of LY354740 has been confirmed by several 
studies (Klodzinska et al., 1999; Linden et al., 2004; Swanson et al., 2004). 
Similarly, systemic administration of this compound was effective to block 
lactate-induced autonomic and behavioural panic responses in rats (Shekhar and 
Keim, 2000). Translation of these effects to humans was demonstrated showing 
that LY354740 blocked the fear-potentiated startle to shock anticipation and the 
anxiogenic effects of CO2 challenge without sedative action (Grillon et al., 2003; 
Schoepp et al., 2003).
 Gender differences are seen in a variety of psychiatric disorders, including 
the prevalence of depression and anxiety disorders: panic with agoraphobia, 
generalized anxiety disorder (GAD) and posttraumatic stress disorder (PTSD) 
occur two to three times more frequently in women than in men (Gater et al., 
1998). Animal studies on anxiety tasks also suggest that, under certain conditions, 
sex differences exist in fear and anxiety-related behaviours (Palanza, 2001). For 
instance, male rodents exhibit more fear-related behaviours than females in 
elevated plus maze test (Imhof et al., 1993; Wilson et al., 2004), whereas females 
are more fearful in the Vogel conflict test (Johnston and File, 1991). Furthermore, 
gender differences in response to drug treatment have been recognized in both 
humans (Pigott, 1999) and animals (Blanchard et al., 1991; Fernandez-Guasti and 
Picazo, 1997). However, all the above-mentioned studies evaluating the anxiolytic 
properties of LY354740 were focused on male experimental animals. Thus, the 
main interest of this study was to test the anxiolytic effects of LY354740 in female 
rats. LY379268, another highly potent and selective mGlu2/3 receptor agonist, 
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has a slightly different pharmacological profile being more potent in comparison 
with LY354740 (Monn et al., 1999). LY379268 has been found to reduce stress-
evoked hyperlactemia (Johnson and Chamberlain, 2002) and norepinephrine 
(NE) release in the prefrontal cortex (Lorrain et al., 2005). We also observed 
reduced exploratory behaviour in the open field at low dose of LY379268, but its 
anxiolytic properties have not yet been tested in specific anxiety-related models 
such as the elevated plus maze test (EPM). The traditional EPM, consisting of 
two open arms crossed with two closed arms all being elevated from the ground 
is a widely used model for studying anxiolytic drugs (Cruz et al., 1994; Rodgers 
and Johnson, 1995). This model is based on the rodent’s innate fear of open and 
elevated places, therefore rats tend to avoid the open arms and stay more on the 
enclosed arms. Anxiolytic compounds typically reduce this open arm-avoidance 
without changing the number of closed arms entries. This fear can be potentiated 
by inescapable stress exposure (IS), which provides a robust anxiety model with 
high predictive validity (Korte and de Boer, 2003). To this end, we tested the 
anxiolytic properties of LY354740 and LY379268 in both male and female rats 
using the traditional as well as the IS-potentiated EPM model. 
The hippocampus, a structure involved in declarative, spatial and contextual 
learning and memory, is particularly sensitive to stress in a gender dependent 
manner. Studies investigating neurogenesis of the dentate gyrus (DG) have 
reported that stress reduces hippocampal plasticity in males with either no effect 
or stimulatory effects seen in females (Gould and Tanapat, 1999; Falconer and 
Galea, 2003; Westenbroek et al., 2004). The DG is also rich in mGlu2/3 receptors 
(Petralia et al., 1996). Moreover, the well established anxiolytic effects of mGlu2/
3 agonists have been associated with suppressed hippocampal neurotransmission 
(Linden et al., 2004; Tatarczynska et al., 2001). Thus, we measured the expression 
of cAMP response-element binding protein (CREB) and its phosporylated form 
(pCREB) by using Western blot analysis to characterize stress and treatment 





Experiments were performed with male (n=48: 210±7 g) and normal cycling female (n=48: 
201±7g) Wistar rats (n=6/group). Animals were individually housed with food and water available 
ad libitum and maintained on a reversed 12/12 h light/dark cycle (lights on at 19:00).  All animals 
were allowed to adapt to the room conditions for at least 1 week before the beginning of the 
experiments. All rats were handled and weighed daily to minimize stress during the experiment. 
Stage of the estrous cycle was assessed in females by stroking them gently on the back, producing 
lordosis during oestrus and also weight loss was observed on the day of oestrus. Females were 
tested randomly throughout their cycle. The Animal Ethics Committee of the University of 
Groningen approved the protocol (DEC: D4324A).  
DRUGS
LY354740 (3 mg/kg; {1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate 
monohydrate}) and LY379268 (1 mg/kg; {(-)-2-oxa-4-aminobicyclo[3.1.0]echane–4,6-
dicarboxylic acid}) were dissolved in saline. In order to perfectly dissolve these compounds (Eli 
Lilly and Company, Indianapolis) in saline, 1 µl of 5N NaOH was added for every mg of LY379268 
(~pH6) and placed in a bath sonicator for a short time. As a positive reference drug, diazepam (1.5 
mg/kg) was dissolved in 50% saline, 5% ethanol and 45% propyleneglycol solution. All solutions 
were freshly prepared before injection and were administered intraperitoneally (i.p.) 30 min prior to 
the EPM test. Control rats received a vehicle injection. For three consecutive days before the test, 
all rats received daily saline injection (i.p.) to habituate them to the procedure.  
ACUTE FOOTSHOCK PROCEDURE (IS) 
The acute footshock procedure was performed as described previously (Trentani et al., 2003). The 
rodent test-chamber consists of a box containing an animal space positioned on a metallic grid floor 
connected to a shock generator and scrambler. Twenty-four rats from each gender were exposed to a 
daily footshock protocol for 2 consecutive days during which 5 inescapable footshocks (IS: 0.8 mA 
intensity, 8 s duration, 15-30 min interval) were applied. A 10 s light signal (on the inner chamber 
wall) preceded each footshock as psychological conditioning to the noxious event. On the third day, 
1 h before the EPM test, only the light signal was given in order to avoid shock-related pain effects. 
Control rats were transported in their homecage two consecutive days to a room with conditions 
similar to the footshock room and stayed there for at least one hour.
ELEVATED PLUS MAZE (EPM)
All behavioural tests were performed between 9 a.m. and 12 a.m. The testing room was illuminated 
by two 25 W bulbs positioned 1 m away from either side of the EPM. On the test day (third day 
of the footshock procedure), animals were transferred to the testing room in their home cages 
and allowed to acclimate for at least 1 h.  The wooden maze (painted black) comprised two open 
arms (OA: 50×10×2 cm) surrounded with a 1 cm high edge and two closed arms with a roof (CA: 
50×10×40 cm), which extended from the central platform (5×5 cm). The maze was elevated 50 cm 
above the floor.
 Animals received either a saline injection or one of the testing compounds (i.p.) 30 min prior to 
testing. Each animal was tested only once. Rats were placed in the centre of the maze facing one of 
the open arms and their behaviour was recorded with a videotracking system for a period of 6 min 
(Etho Vision 3.1.16, Noldus Information Technology, Wageningen, The Netherlands). As anxiety 
index, three parameters were calculated (Rodgers and Johnson, 1995): percentage of the OA entries 
(100 × OA/total arm entries), percentage of the time spent in the OA (100 × time OA/ total time) 
and percentage of the time spent in the closed arms. A 10 cm large “entry” zone was added between 
the open arms and the center so that the rat should pass this zone for an OA entry to be recorded. 
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Since the closed arms had a roof, the software calculated CA activity when the position of the rat 
on the EPM was not visible. 
To assess general activity the CA entries, the total entries and the mean velocity in the open zones 
of the EPM (open arms + center) were measured. In addition, the time spent in the center was 
calculated as a useful index for decision-making/risk assessment (Rodgers and Johnson, 1995). 
After each trial, the maze was cleaned with an alcohol solution. 
Table 1. Experimental protocol. 
CORTICOSTERONE RADIO IMMUNO-ASSAY
Thirty min after the EPM test, rats were anaesthetised with 5% isoflurane and decapitated; brains 
were quickly removed and frozen in -80°C and trunk blood was collected for corticosterone radio 
immuno-assay (RIA).
The corticosterone fraction was extracted from the plasma (10 µl) with Chromosorb (Alttech) and 
30% dichloromethane (Rathburn 1001). Before the extraction a trace amount of 3H labelled (200 
Bq) corticosterone (TRK-406 Amersham) was added to the samples to determine recovery which 
was 20%. A standard curve was determined by using non-labelled corticosterone, which was treated 
in the same way as the extracted plasma samples. 
For the quantification samples were mixed with 3H (500 Bq) labelled corticosterone and polyclonal 
antibody raised against corticosterone (rabbit nr 568 UMCG). Tubes were incubated at 60°C for 30 
min and the equilibrium reaction was established in a water/ice bath for 1 hour. The reaction was 
stopped by adding charcoal suspension and incubated for 15 min in the water/ice bath. Tubes were 
centrifuged for 15 min at 3000*g and 4°C to spin down the charcoal bound with free corticosterone. 
The supernatant was poured into 1 ml of scintillation fluid (Ultimagold XR, Canberra Packard) and 
samples were counted in a β-counter for 4 min or 4000 presetcounts. The amount of corticosterone 
was calculated from the standard curve.
WESTERN BLOT ANALYSIS 
Serial 300 µm coronal sections of the cerebrum were made with a cryostat microtome (-15°C) and 
kept frozen on dry ice. Tissue samples were dissected from the dentate gyrus (DG: bregma -2.45 
to -2.85; Fig.1 {Swanson, 1992}) by using the “Palkovits Punch” technique (needle diameter 1.22 
mm, Stoelting Co., Illinois, USA). Two punches per animal per area were taken and diluted in 50 
μl buffer (50 mM Tris ph 6.8, 1% SDS, 5% β-mercaptoethanol, 1 mM NaVO4, 10 mM NaF, 1 mM 
EGTA and Complete protease inhibitors Roche). Brain tissue was homogenized and then heated for 
2 min at 96°C. The samples were stored at -80°C.
The expression of cAMP response-element binding protein (CREB), phosphorylated (p)CREB 
(Upstate Biotechnology, Lake Placid, NY) and β-actin as a loading control (Abcam, Cambridge, 
UK) was estimated by Western blot analysis. Protein samples (5 μl) were combined with SDS-
bromophenol blue (5 μl) reducing buffer with 100 mM DTT and then heated for 5 min at 96°C 
to limit the formation of high molecular weight receptor aggregates. Western blot analyses 
were carried out using 10% SDS polyacrylamide gels; gels were electroblotted (Supported 
Nitrocellulose Membrane, Biorad) for 1 h using a wet electroblotting system (Biorad, Mini 
Trans-Blot Electrophoretic Transfer Cell), and filters were blocked for 1 h in PBS buffer (pH 
7.4) containing 3% non-fat dry milk. Blots were then incubated overnight at 4°C with primary 
polyclonal antibodies (1:1000 for CREB and pCREB and 1:10000 for β-actin) diluted in 3% non-
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fat dry milk-PBS solution. Blots were washed three times for 10 min with PBS buffer and then 
incubated for 1 h with secondary antibodies (peroxidase-coupled anti-rabbit for CREB and pCREB 
and peroxidase-coupled anti-mouse for β-actin, Amersham Bioscience UK) diluted (1:5000) with 
3% non-fat dry milk-PBS. Immunostaining was revealed by the enhanced ECL Western Blotting 
analysis system (Syngene, Westburg, The Netherlands). The intensity of the bands was quantitated 
by image analysis. Membranes were washed and re-probed with the antibody to β-actin for loading 
control. CREB and pCREB signals were normalized by the levels of β-actin and expressed as a 
percentage of the corresponding values for unstressed controls on the same blots.
Figure 1. Atlas image represents 
the approximate brain level where 
dentate gyrus was dissected. 
STATISTICAL ANALYSIS
Data are presented as mean ± SEM. Statistical analyses were done with SPSS (version 12.0) and 
P<0.05 was considered significant. All investigated parameters were analysed with a univariate 
ANOVA with gender, inescapable footshock (IS) and drug treatment as between subject factors. 
Sphericity assumed modelling, with Huynh-Feldt adjustment, was applied. A LSD post hoc test was 
used for pair-wise comparisons.
RESULTS
GENDER DIFFERENCES IN EPM BEHAVIOUR
As Fig. 2 illustrates, females showed more open arms (OA) activity than 
males: there was a significant gender effect on %OA entries (F (1, 9) =7.879, 
P<0.020) and %OA duration F (1, 9) =12.562, P<0.006). Accordingly, males 
showed more closed arms (CA) activity. They spent more time (F (1, 9) =21.537, 
P<0.001) and entered more often into the CA (F (1, 9) =5.572, P<0.043). There 
was no difference in center duration, number of total entries and mean velocity.
EPM activity did not seem to be affected by oestrus cycle, since activity of 
females in oestrus during the EPM test was similar to that of non-oestrus females 
(not shown).  
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IS  EFFECTS ON BEHAVIOUR
Responses to acute IS treatment showed gender differences (Fig.2). There was 
significant gender x IS interaction in %OA entries (F (1, 19) =11.013, P<0.004), 
OA duration (F (1, 19) =13.500, P<0.002) and %CA duration (F (1, 19) =29.448, 
P<0.001). In females IS increased anxiety-related behaviour: they showed less 
OA activity (%OA entries, P<0.05; %OA duration, P<0.011) and increased CA 
activity (%CA duration, p<0.001) compared to control females. In contrast, 
stressed males avoided the closed arms (%CA duration, P<0.026) and they 
spent more time on open arms (%OA entries, P<0.016; %OA duration, P<0.027) 
compared to control males. 
IS did not affect locomotion-related parameters in females but it reduced CA 
entries in males (F (1, 19) =7.714, P<0.012). IS had no effect on center duration.
Figure 2. Gender 
differences in EPM 
behaviour of control and 
stressed rats. Control 
females spent more 
time and entered more 
often into the open arms 
compared to control 
males. Acute inescapable 
footshock stress (IS) 
had opposite effect on 
EPM behaviour: stressed 
females showed reduced 
open arms activity 
while stressed males 
avoided closed arms. 
*P<0.05; significant 






EFFECTS OF MGLU2/3 RECEPTOR AGONISTS AND DIAZEPAM ON BEHAVIOUR   
In general, treatment with LY compounds had no effect on spontaneous behaviour 
in males. In females LY354740 increased general activity-related parameters 
(total entries; F (3, 37) =4.110, P<0.013 and mean velocity; F (3, 37) =3.121, 
P<0.037). LY379268 increased %CA duration (F (3, 37) =5.753, P<0.002) 
without affecting open arm and general activity parameters but it reduced the 
time spent in the center (F (3, 37) =4.110, P<0.009). Diazepam had no effects on 
any parameters investigated irrespective of gender (data not shown).
Three-way ANOVA showed significant gender x IS x treatment interaction 
in %OA entries (F (3, 73) =4.360, P<0.007), %OA duration (F (3, 73) =3.586, 
P<0.018) and %CA duration (F (3, 73) =4.702, P<0.005). Table 2 provides an 
overview of different drug effects on stress-induced behaviour.
In females, LY354740 and LY379268 as well as diazepam could restore IS-
evoked decrease in OA activity, whereas only diazepam was effective in reversing 
the increased %CA duration (P<0.043).
In males, LY379268 and diazepam could restore IS-induced decrease in %CA 
duration and the increase in OA activity, whereas LY354740 was ineffective. 
LY379268 and diazepam also could reverse the IS effect on CA entries in males 
(F (3, 73) =4.360, P<0.007).
Table 2. Treatment effects on IS-induced behaviour in female and male rats. The + indicates P<0.05 
for restoration effects on IS-induced behaviour. The ― indicates lack of  treatment effect.
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PLASMA CORTICOSTERONE
Control females had higher plasma corticosterone levels compared to control 
males (F (1, 9) =18.724, P<0.002). Following acute IS protocol, females 
showed a reduction in plasma corticosterone level (P<0.001) whereas it had 
no effect in males (gender x IS interaction: F (1, 19) =7.526, P<0.013). None 
of the compounds could restore this IS effect in females. ANOVA did not show 
pretreatment x treatment interaction, although LY379268 appeared to normalize 
corticosterone level in stressed females (Fig. 3). 
Treatment with LY compounds or diazepam did not alter basic levels of 
corticosterone irrespective of gender. 
Figure 3. Plasma 
c o r t i c o s t e r o n e 
concentration (nmol/
l) measured 30 min 
after the EPM test. 
*P<0.05; significant 





Expression of CREB and pCREB showed gender differences in the DG: 
control males had higher levels of CREB (F (1, 11) =6.006; P<0.032) and pCREB 
(F (1, 11) =5.484; P<0.039) than control females (Fig. 4).
Treatment with LY354740 did not alter CREB expression irrespective 
of gender while LY379268 and diazepam had an opposite effect (gender x 
treatment interaction: F (3, 37) =7.221; P<0.001). In females LY379268 (+61%, 
P<0.001) and diazepam (+41%, P<0.011) increased CREB levels compared 
to control animals. In contrast, both compounds reduced CREB expression in 
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males, however only administration of LY379268 caused a significant decrease 
(-29%, P<0.012). None of the compounds altered pCREB expression in control 
animals.
Acute IS procedure led to a trend in reducing CREB level in males but not in 
females (IS x gender interaction; F (1, 19) =4.032; P< 0.059). Treatment with 
LY379268 (IS x treatment interaction: F (1, 17) =4.942, P<0.040) and diazepam 
(F (1, 17) =8.177; P<0.011) but not LY354740 could prevent the IS induced 
reduction of CREB in males. Interestingly, diazepam increased CREB in stressed 
females (F (1, 17) =13.073; P<0.002).
IS had no effect on pCREB expression independent of gender. Nevertheless, 
all three compounds increased pCREB levels in stressed females (LY354740; 
25%, P<0.038; LY379268: 38%, P<0.016 and diazepam: 138%, P<0.001) but not 
in stressed males (gender x treat interaction: F (3, 61) =2.754; P<0.05).  
Figure 4. (A) Gender differences in CREB and pCREB expression in the dentate gyrus. Data 
were calculated by densitometric analysis as the ratio between the CREB or pCREB and β-actin. 
Data are means ± SEM of 5–6 determinations. (B) Representative immunoblot of CREB/pCREB 
(43 kD) and β-actin in the dentate gyrus of rats.*P<0.05; significant gender differences in protein 
expression.
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Figure 5. Changes in the expression of CREB in the dentate gyrus as assessed by Western blot 
analysis. Data are expressed as percent of the corresponding values found in control rats and were 
calculated by densitometric analysis as the ratio between CREB and β-actin. Data are means ± 
SEM of 4–6 determinations. *P<0.05; significant treatment effect compared to control protein 
expression.  #P<0.05; significant stress effect. +P<0.05; significant restoration effects of treatment 
on stress-induced changes. 
Figure 6. Changes in the expression of pCREB in the dentate gyrus as assessed by Western blot 
analysis. Data are expressed as percent of the corresponding values found in control rats and were 
calculated by densitometric analysis as the ratio between pCREB and β-actin. Data are means ± 





While recent reports strongly suggest a role for mGlu2/3 receptors in the 
modulation of anxiety and stress-related disorders (Schoepp et al., 2003), all these 
studies focused on male experimental subjects ignoring gender differences in 
anxiety/stress-related behaviour and in response to psychoactive drugs (Johnston 
and File, 1991; Wilson et al., 2004; Palanza, 2001). In agreement with this notion, 
here we showed that females exhibited less anxiety-related behaviour i.e. they 
spent more time in the open arms of the elevated plus maze (EPM) compared to 
males. In addition, pretreatment with mGlu2/3 receptor agonists influenced the 
spontaneous behaviour only in females but not in males: LY354740 increased 
general activity, while LY379268 increased the time spent in the closed arms. It 
should be noted that, these effects of mGlu2/3 receptor agonists did not change 
the open arm activity compared to control females. Similarly, we did not observe 
anxiolytic effects of diazepam in non-stressed rats irrespective of gender. 
It has been demonstrated that previous handling and edges around open arms 
can exert anxiolytic action resulting in increased open arm activity (Andrews 
and File, 1992; Treit et al., 1993; Fernandes and File, 1996). Our experimental 
circumstances such as handling history, the design of the apparatus (see materials 
and methods section) and reversed light/dark cycle (i.e. tests were conducted 
in the active phase of the animals) could result in stress-free experimental 
conditions, masking possible anxiolytic effects of the mGlu2/3 receptor agonists 
and diazepam in the EPM test under basal conditions. 
Acute inescapable foot-shock (IS) prior to EPM test influenced the 
spontaneous behaviour sex-dependently. IS increased open arms avoidance in 
females without reduction in general activity indicating that footshock exposure 
affected only anxiety-related parameters. To the contrary, stressed males showed 
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an increase in open arm activity and a decrease in closed arm entries. There 
are evidences for sex differences in response to footshock which may differ 
according to the behavioural test. For instance, exposure to IS more strongly 
reduced activity in a subsequent open-field test and increased more the latency to 
escape in the shuttlebox in males than in females (Steenbergen et al., 1991). Step-
through passive avoidance studies showed that, when a footshock was presented 
upon entering a dark compartment, more male than female rats refrained from 
re-entering the dark compartment (van Haaren and van de Poll, 1984; Kudo et 
al., 2004). Moreover, male rats acquire an associative learning task faster and 
emit more conditioned responses following one acute stressful experience (Shors, 
2001), whereas female rats exposed to the same stimulus are learning impaired, 
emitting fewer conditioned responses (Wood and Shors, 1998; Wood et al., 
2001). Although speculative, it can be argued that in the present study stressed 
males became conditioned to contextual cues that are in common with the test 
situation. In this case, the closed arms could be associated with the shock box 
and the aversive stimuli resulting in a decreased number of entries into the closed 
arms. Consistent with this finding, a recent report has demonstrated that an acute 
footshock produced an increased time spent in the open arm in male Wistar rats, 
but a decreased this parameter in Sprague-Dawley rats (Belda et al., 2004). Thus, 
it is conceivable that beside gender, the effect of an acute footshock in the EPM 
also depends on the rat strain. 
 Nevertheless, pretreatment with LY379268 and diazepam could restore IS 
effects on EPM performance in both sexes. LY354740, however, was effective 
only in stressed females, but not in stressed males. Since the more potent 
structural analogue LY379268 was able to prevent IS-induced changes in males, 
the lack of LY354740 effect might be attributable to the dosage (3 mg/kg) which 
is indeed lower than those used in other studies (10-20 mg/kg) in EPM test (Ferris 
et al., 2001; Linden et al., 2004). This might also imply that males and females 
have different pharmacokinetic profiles for these drugs.
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Corticosterone and Western blot analysis
In addition to sex differences in behaviour, we observed 2-fold higher 
corticosterone levels in females than in males, consistent with other studies 
(Weinstock et al., 1998; Trentani et al., 2003). Administration of LY354740 and 
LY379268 did not alter baseline corticosterone levels supporting the hypothesis 
that the HPA axis is predominantly under the control of group I and group III 
mGlu receptors, whereas mGlu2/3 receptors play a minor, if any, role (Johnson 
et al., 2001). 
Interestingly, stressed females showed reduced plasma corticosterone levels 
while IS had no effect on corticosterone in males. Previous observations in our lab 
showed similar reduction in corticosterone in acutely stressed females two hours 
after re-exposure to the shock box (Lin et al., personal communication). There are 
evidences showing that re-exposure to a stressor even days after a single aversive 
procedure leads to an increased corticosterone negative feedback (Marti et al., 
2001; Louvart et al., 2006).  Furthermore, pretreatment with glucocorticoids 
or glucocorticoid receptor agonists (at least 60 min prior to stressor) suppress 
subsequent stress-induced HPA axis activity (Ginsberg et al., 2006). In our 
experimental set up the time interval was 1 hour between the last stress-box 
exposure (psychological stressor) and the elevated plus maze test (mild stressor). 
It can be argued that the first stressor increased corticosterone levels that in 
turn enhanced the negative feedback mechanism preventing further increase 
in corticosterone levels, even after the EPM test. Given the facts that female 
rodents release more corticosterone than males in response to stress (Handa et 
al., 1994; Rivier, 1999), a stronger negative feedback on HPA axis resulting in 
reduced corticosterone levels in stressed females is plausible. Consistent with 
this result, a recent report showed a sex-dependent HPA axis response to repeated 
stress, demonstrating a blunted corticosterone response in females, whereas such 
an effect was not observed in males (Louvart et al., 2006). Nevertheless, in the 
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recent study neither mGlu2/3 receptor agonists nor diazepam could prevent IS 
effect on corticosterone levels in females. 
Western blot assay on the DG revealed several gender differences in CREB 
and pCREB protein expression. First, control males showed higher expression of 
both proteins. Second, we observed increased CREB expression in females and 
a reduction in males following administration of LY379268 and diazepam under 
control conditions. 
Third, in males acute stress reduced the level of CREB without changing 
pCREB expression, whereas in females no changes were observed following IS. 
These later results are in agreement with other reports showing that females are 
less susceptible to stress-induced hippocampal plasticity and cell proliferation 
while consistent suppression effects of stress on these parameters have been 
found in males (Falconer and Galea, 2003; Mirescu and Gould, 2006). 
Similar to the reversal effects of LY379268 and diazepam on behaviour, 
treatment with these compounds, but not with LY354740, could normalize  CREB 
levels in stressed males without altering pCREB. In stressed females, however, 
all three compounds increased pCREB expression but there were no changes in 
CREB. These findings may indicate that regarding regulation of CREB function, 
mGlu2/3 receptor agonists have a profile similar to diazepam which is gender 
dependent: in males normalization of CREB levels while in females increased 
activation of CREB appears to be involved in the anxiolytic action of these 
compounds. It is conceivable that inhibition of neuronal excitability is related 
to these effects, since both mGlu2/3 receptor agonists (Moghaddam and Adams, 
1998; Lorrain et al., 2003a) and diazepam (Karreman and Moghaddam, 1996) 
can suppress evoked glutamate release. However, the signalling pathway by 
which the mGlu2/3 receptors influence CREB function remains to be explored. 
The mGlu2/3 receptors negatively modulate glutamate release by inhibiting 
adenylyl cyclase resulting in the downregulation of the cAMP-dependent protein 
kinase A (cAMP/PKA) cascade. In addition, activation of protein kinase C 
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(PKC) and mitogen-activated protein kinase (MAPK) is also associated with 
mGlu2/3 receptors (Matrisciano et al., 2002; Kahn et al., 2001). Since CREB is a 
convergence point of these above mentioned signal transduction pathways, it will 
be interesting to examine which could act as an effector downstream to mGlu2/3 
receptors to modulate CREB function. 
CONCLUSION
The present experiment provides further evidence for the role of mGlu2/3 
receptors in the treatment for anxiety/stress related disorders. To our best 
knowledge, this is the first study demonstrating anxiolytic properties of 
LY354740 in females and of LY379268 in relation of specific anxiety model. 
Similar to diazepam (positive control drug), LY379268 could restore stress-
induced changes in EPM performance irrespective of gender, whereas LY354740 
was effective only in stressed females. As Western blot analysis in the DG 
indicated, normalization of CREB levels in males, while increased activation of 
CREB (i.e. increased pCREB) in females appear to be involved in the anxiolytic 
action of mGlu2/3 agonists and diazepam.
Control animals showed several sexual dimorphisms in anxiety-related 
behaviour, corticosterone levels and CREB/pCREB expression. Accordingly, 
these parameters changed in a gender-dependent manner following acute stress or 
drug treatment. Concerning these substantial gender differences and the fact that 
anxiety/stress related disorders are more common in women, the use of females 






DISCUSSION AND CONCLUDING REMARKS
The objective of the studies comprised in this thesis was to further explore the 
proposed therapeutic properties of two highly selective group II metabotropic 
glutamate (mGlu2/3) receptor agonists LY354740 and LY379268. 
We used the ketamine model of schizophrenia (chapter 2) to test the possible 
antipsychotic effects of these compounds in rats. In these experiments mGlu2/
3 receptor agonists were applied either subchronically (chapter 3) or acutely 
(chapter 4), and investigated whether they could prevent ketamine-evoked 
motor impairment or sensorimotor gating deficits. Measuring c-fos expression 
throughout the brain and ex-vivo neurotransmitter levels in the dentate gyrus by 
HPLC analysis provided insight how the mGlu2/3 receptor agonists influence 
both basal and ketamine-induced neuronal activity.
Although both LY354740 and LY379268 were not effective in restoring 
ketamine-induced symptoms, during these experiments both drugs per se 
produced some anxiolytic-like effects. As a follow-up study, therefore, we 
examined the possible anxiolytic potential of mGlu2/3 receptor agonists using 
both traditional- and fear-potentiated elevated plus maze (chapter 5). Gender 
differences in behaviour and CREB/pCREB expression in the dentate gyrus were 
compared. 
THE ROLE OF MGLU2/3 RECEPTORS IN BASAL HIPPOCAMPAL FUNCTION
The hippocampus is a key limbic structure for processing emotional 
information and encoding of memory. The mGlu2/3 receptors regulate neuronal 
excitability and synaptic transmission in this region. Group II mGlu receptors 
are highly expressed in the terminal fields of the perforant path, input from the 
entorhinal cortex in the dentate gyrus (DG) and the CA1 stratum lacunosum 
moleculare as revealed by both immunohistochemistry (Petralia et al., 1996; 
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Shigemoto et al., 1997; Ohishi et al., 1998) and receptor-binding studies (Mutel 
et al., 1998; Schaffhauser et al., 1998). 
Application of group II mGlu receptor selective agonists, including LY354740, 
inhibits synaptic transmission in the hippocampus in vitro (Kilbride et al., 1998; 
Kew et al., 2001). Activation of mGlu2/3 receptors by synaptically released 
glutamate has been observed in the hippocampal perforant pathway following 
high frequency burst stimulation or blockade of glutamate uptake which in turn 
led to rapid inhibition of transmitter release (Scanziani et al., 1997; Kew et al., 
2001). However, at low-frequency stimulation mGlu2/3 receptors remain non-
activated. Based on these in vitro data it was proposed that mGlu2/3 receptors 
do not play a role in modulation of neurotransmission under basal conditions and 
that activation of these receptors requires a spread of glutamate from the release 
site. 
A recent report, however demonstrated (Linden et al., 2005b), that blockade of 
mGlu2/3 receptor by a selective antagonist, LY341495 in vivo, produced robust 
c-fos induction across the brain including the CA1 and CA3 region, but not in 
the DG. In contrast, activation of mGlu2/3 receptors by LY354740 reduced c-
fos expression in the DG while no changes were observed in CA1-CA3 regions 
(Linden et al., 2005b). Consistent with the latter, we found decreased c-fos 
expression in the DG as well as in the CA1 following both subchronic treatment 
with LY354740 and acute treatment with LY379268 (Fig.1) whereas other brain 
areas including CA3, prefrontal cortex, amygdala, hypothalamus and nucleus 
accumbens (chapter 3, Table 1) were not affected. 
Altogether, under basal conditions activation of mGlu2/3 receptors by 
endogenous glutamate is important in the regulation of neuronal excitability 
throughout the brain but not in the dentate gyrus. Pharmacological blockade 
of mGlu2/3 receptors within these areas results in cell activation while agonist 
action has no effect. In the DG, however, mGlu2/3 receptor activation by selective 
agonists leads to a suppression in neuronal activity. As the DG is the main input to 
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the hippocampus providing multimodal sensory information derived from cortical 
zones (Jones, 1993), its target cells need to receive highly focused excitation, 
with exclusion of irrelevant signals (Sloviter, 2003). Although speculative, 
suppressed c-fos expression in DG following mGlu2/3 receptor activation by 
mGlu2/3 receptor agonists (LY354740 and LY379268) might reflect reduced cell 
activity which in turn contributes to the information “filtering” mechanism, even 
under basal conditions.
Figure 1. Acute treatment with 
LY379268 (3mg/kg) reduced 
c-fos expression (*P<0.05) in 
dentate gyrus and CA1 region 
of hippocampus (unpublished 
observation related to chapter 4).
HIPPOCAMPAL GLUTAMATE RECEPTORS AND SENSORIMOTOR GATING DEFICIT
Substantial evidence for the hippocampal regulation of information processing 
come from animal studies showing that local pharmacological injections or 
neonatal lesion of this area leads to PPI deficit. Glutamate transmission via 
NMDA receptors in the hippocampus plays a major role in mediation of PPI 
as both blockade (chapter 2-4) or stimulation (Swerdlow et al., 2001) of these 
receptors induce sensorimotor gating deficits. In fact, c-fos expression in the 
hippocampus was found to decrease by increasing the ketamine dose (chapter 2) 
while repeated ketamine challenge (3 consecutive days) resulted in a significant 
reduction of c-fos in the DG but not in the CA1-CA3 (chapter 3). One possible 
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explanation is that the dose of ketamine (12 mg/kg) was sufficiently high to block 
the NMDA receptors of both excitatory input to pyramidal cells and interneurons 
in the DG (Grunze et al., 1996; Greene, 2001). Since we used systemic ketamine 
administration resulting in profound dose independent c-fos induction (but never 
reduction) in other brain regions involved in regulation of PPI, disturbance in 
the DG per se cannot account for the observed PPI deficit. Rather, the extent of 
disruption in the DG determines the degree of the deficit in information processing 
and thus the final behaviour output following ketamine challenge (Grace, 2000). 
Consistent with previous reports (Ossowska et al., 2000; Schreiber et al., 
2000; Henry et al., 2002), pretreatment with LY354740 and LY379268 could not 
block the ketamine-evoked PPI deficit. As the HPLC data showed, LY379268 
could prevent effects of ketamine on glutamate but not on monoamine (dopamine 
and serotonin) levels in the DG (chapter 4) indicating that modulation of 
glutamatergic transmission by mGlu2/3 receptors is not sufficient to block 
ketamine effects on PPI. These data together with in vivo microdialysis 
studies (Lorrain et al., 2003a; Moghaddam and Adams, 1998) also imply that 
ketamine and other NMDA antagonists have broad-spectrum effects on different 
neurotransmitter systems which is not secondary to increased glutamate efflux 
as earlier proposed (Moghaddam et al., 1997; Mathe et al., 1998). The main 
effect of ketamine and other NMDA antagonists is thought to be a blockade 
of NMDA receptors located on GABA interneurons. This antagonism on 
NMDA receptors is not selective: ketamine may block GABAergic drive onto 
glutamate, serotonin, dopamine and noradrenalin terminals, thus disinhibiting 
the release of these neurotransmitters. Thus, some of these ketamine effects are 
independent of glutamate neurotransmission, which probably cannot be restored 
by administration of highly selective mGlu2/3 receptor agonists.  
Extra-synaptic localization of group II mGlu receptor on nonglutamatergic 
neurons has been described and suggests a possible presynaptic heteroreceptor 
role for these receptors. Indeed, electrophysiological and biochemical studies 
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have shown that mGlu2/3 receptor agonists  suppress the release of GABA 
from neurons (Anwyl, 1999; Cartmell and Schoepp, 2000) and  reversibly 
reduce the amplitude of GABA-mediated inhibitory postsynaptic potentials 
in a number of tissues including cerebral cortex, hippocampus, thalamus, 
and spinal cord (Anwyl, 1999). The net effect of mGlu2/3 receptor activation 
on brain excitability depends on the relative tone of both excitatory versus 
inhibitory input to the system (Schoepp, 2001). The work of Mitchell and Silver 
(2000) indicates that the spillover of glutamate from mossy fiber terminals can 
activate presynaptic mGlu receptors on GABAergic nerve terminals, and this 
leads to inhibition of GABA release onto principal excitatory neurons. This 
represents a heterosynaptic mechanism by which inhibitory interneurons sense 
excitatory activity of neighboring excitatory synapses. In this manner, the carried 
information of the active excitatory circuit can be enhanced by locally reducing 
GABAergic inhibition under physichological conditions.  
Thus, empirically mGlu receptor-mediated presynaptic modulation of 
GABA release may be a mechanism for enhancing cell excitability which 
raises a methodological question concerning the ketamine model: if under 
basal conditions mGlu2/3 receptor activation reduces the inhibitory tone (as we 
applied the mGlu2/3 receptor agonists to healthy rats 30 min prior to ketamine 
challenge), a subsequent NMDA blockade on GABAergic neurons would lead to 
a more profound excitation and thus an exaggerated behavioural deficit. Such a 
synergistic interaction could explain the enhanced ketamine-evoked PPI deficits 
we observed following both LY354740 (chapter 3, Fig. 1A) and LY379268 
(chapter 4, Fig. 4) pretreatment.  As discussed later, it might be more appropriate 
to test the antipsychotic potential of these compounds following induction of 
pathological conditions in which the excitatory tone is already elevated, for 
instance, by chronic treatment with NMDA antagonists. 
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ANXIOLYTIC EFFECTS OF MGLU2/3 AGONISTS
Given the important role of the hippocampus in processing novel spatial 
information, the amounts of exploration of the new environment or experience 
can account for the corresponding hippocampal activity (Pace et al., 2005). 
Thus, the reduced c-fos expression in the DG and in the CA1 following mGlu2/
3 receptor agonists may correspond to the decreased time spent rearing in the 
open field (LY354740; Fig. 2 and LY379268; chapter 4, Fig. 3) which was 
interpreted as a decrease in novelty stress-evoked exploratory behaviour. In fact, 
the anxiolytic effects of this compound have been associated with suppressed 
hippocampal neurotransmission: intrahippocampal administration of LY354740 
exhibited anxiolytic activity in the conflict drinking test (Tatarczynska et al., 
2001) whereas systemic LY354740 prevented stress induced c-fos expression in 
the hippocampus (Linden et al., 2004). 
Figure 2. Subchronic 
administration of LY354740 
(0.3-10 mg/kg) reduced 
exploratory behaviour expressed 
as time spent rearing. The dose of 
3 mg/kg of LY354740 decreased 
significantly this behaviour at all 
the three time point (*P<0.05), 
whereas the 0.3 and 10 mg/kg 
showed a tendency toward it 
(unpublished observation related 
to chapter 3).  
The mechanisms by which mGlu2/3 receptor agonists act as anxiolytics may 
involve modulation of both glutamatergic and GABAergic neurotransmission 
depending on the behaviour test. Administration of benzodiazepine (GABA) 
antagonist, flumazenil has been shown to block the anxiolytic effect of LY354740 
in elevated plus maze (Ferris et al., 2001) but not in fear-potentiated startle 
(Tizzano et al., 2002). On the other hand, flumazenil blocked the anxiolytic effect 
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of diazepam in both paradigms. Overall, these data indicate that the anxiolytic 
action of LY354740 in fear-potentiatied startle is mechanistically distinct from 
diazepam, but both compounds share a common profile in the EPM. 
Behaviourally we found that both LY379268 and LY354740 restored stress 
effects on EPM performance similar to diazepam and that these effects were not 
gender dependent (chapter 5). Western blot analysis of proteins extracted from 
the DG showed that mGlu2/3 agonists and diazepam influenced CREB/pCREB 
expression in similar manner however gender dependently. While anxiolytic 
effects of these compounds were associated with increased pCREB expression 
in females, both LY379268 and diazepam restored stress-induced reduction in 
CREB levels in males. Explanation for the functional role of these data require 
a carefully designed framework i.e. interaction of mGlu2/3 receptors and 
upstream regulators of CREB cascade (PKA, PKC or MAPK) and downstream 
consequences of CREB activation (BDNF or c-fos expression). Nevertheless, 
these data suggest that mGlu2/3 receptor agonists share a common mechanism 
with diazepam in anxiolytic actions on EPM performance which are gender 
dependent in relation to signal transduction processes. 
It has been noted that LY354740 does not produce ataxia or suppress motor 
coordination, effects that are typically associated with benzodiazepine treatment 
(Helton et al., 1998). However, the more potent mGlu2/3 receptor agonist 
LY379268 produced motor impairment on rotorod performance which was 
absent after 4 days of repeated administration (Cartmell et al., 2000a). In the open 
field we observed immobilization effects following 2 and 3 mg/kg of LY379268 
which was associated with an increased startle reflex and other anxiogenic-like 
side effects (chapter 4). In contrast, at the dose of 1 mg/kg LY379268, animals 
did not exhibit any side effects in the open-field (chapter 4) and it restored stress 
effects on EPM performance (chapter 5).
 It has been suggested that side effects linked to benzodiazepine treatment 
are attributable to actions on α1 subunit-containing GABA receptor complexes 
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(Mohler et al., 2001) while the anxiolytic properties of benzodiazepines have been 
attributed to their interaction with receptors containing the α2 subunit-receptor 
subtype (Low et al., 2000). The α2 subunit-GABA
A
 receptors display a distinct 
and robust distribution in hippocampus, where they are found on glutamatergic 
pyramidal cells (Nusser et al., 1996; Fritschy et al., 1998). Interestingly, LY354740 
binding exhibits a strikingly similar overlap with α2 subunit-GABA
A
 receptor 
binding in the rat brain (Wright et al., 2001; Rudolph, 2001). These findings are 
indicative of a potential mechanism through which benzodiazepines and group 
II mGlu receptors might exert similar effects on excitability and thus anxiety 
state. In regard of anxiolytic action, for example, facilitation of GABAergic 
transmission by stimulation of α2 subunit-containing receptors on pyramidal 
cells would result in hyperpolarization of these cells whereas stimulation of 
presynaptic mGlu2/3 receptors would result in suppression of excitatory input 
to the same pyramidal cells. On the other hand, high dose of LY379263 might 
recruit mGlu2/3 receptors located presynaptically to pyramidal cell containing α1 
subunit-GABA
A
 receptors, which in turn could lead to side effects.
ACTIVATION OF MGLU2/3 RECEPTORS IN TERM OF LEARNING AND MEMORY
 LY354740 impaired performance in the water maze test, a hippocampus 
dependent measure of spatial learning and long-term memory (Higgins et al., 
2004). In addition, LY354740 disrupted cognitive function in both the operant 
delayed (non)-match to position task (Higgins et al., 2004) and the discrete 
paired-trial variable-delay alternation task (Aultman and Moghaddam, 2001), 
primarily paradigms of working memory. Based on these findings, it has been 
proposed that activation of presynaptic mGlu2/3 receptors suppress the slow 
asynchronous phase of glutamate release, of which the presumed function is 
to maintain the initial activation of postsynaptic NMDA receptors involved in 
mnemonic coding (Aghajanian and Marek, 1999; Aultman and Moghaddam, 
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2001). Since the above-mentioned behavioural impairment was evident in both 
an appetitively (delayed (non)-match to position) and an aversively (Morris water 
maze) motivated task, it is highly unlikely that these effects of LY354740 are a 
consequence of any anxiolytic activity of this drug. 
 Deletion of both mGlu2 and mGlu3 disrupted anxiolytic activity of 
LY354740 (Linden et al., 2005a). Deletion of mGlu3, but not mGlu2, prevented 
the LY354740-induced reduction in c-fos expression in the DG and CA1 (Linden 
et al., 2006). These data indicate the requirement of concomitant activation of 
both receptors throughout the brain to exert anxiolytic action, which might be 
associated with reduced hippocampal neuronal activity via modulation of mGlu3 
receptor.
 As mentioned in the general introduction, mGlu3 receptors (but not mGlu2) 
are expressed by glial cells (Tamaru et al., 2001). The roles of these mGlu3 
receptors, however, are less understood than are those for mGlu2 receptors. The 
uptake and release of glutamate from glia play a fundamental role in controlling 
extracellular concentrations of glutamate and thus neuronal synaptic activity. 
The presence of mGlu3 receptors on glia may reflect a mechanism to control 
indirectly the activity of neurons via reduction of glutamate release from glia 
stores (also see Winder and Conn, 1996).
 The mGlu3 receptors are also expressed postsynaptically, where they 
probably induce hyperpolarizations (at least in the rat amygdala neurons) 
possibly via a mechanism involving activation of pertussis-sensitive potassium 
currents (Holmes et al., 1996). These postsynaptic mGlu3 receptors (and possibly 
post-synaptic mGlu2 receptors) may function to modulate neuronal excitability 
in this manner. 
Altogether, it is tempting to speculate that activation of glial and postsynaptic 
mGlu3 receptors by LY354740 leads to reduced neuronal activity in the DG and 
in the CA1 which in turn modulate hippocampus dependent learning and memory 
processes. Although mGlu2 receptors in other brain areas may also contribute to 
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these mechanisms, as mGlu2 receptor knockout mice did not show deficits in the 
water maze test following LY354740 treatment (Higgins et al., 2004). 
By contrast, LY354740 at the same doses, which impaired the delayed 
alternation performance task, reversed the working memory disruption induced 
by NMDA antagonist PCP (Moghaddam and Adams, 1998). Similarly, ketamine-
induced cognitive impairment in normal human volunteers was prevented by 
LY354740 (Krystal et al., 2005). Thus, the mechanism by which mGlu2/3 receptor 
agonists affect cognition under normal conditions is likely to be distinct from its 
effect during pathological conditions and detrimental effect of mGlu2/3 receptor 
agonists on learning and memory in a healthy brain should not detract from their 
potential clinical usefulness. In this regard, it will require careful examination to 
study the role of mGlu3 receptor versus mGlu2 receptors in cognitive processes 
when the appropriate tools (selective agents and/or receptor knockout animals) 
become available
REMARKS CONCERNING DRUG TESTING IN ANIMAL MODELS
The studies described in this thesis showed that modulation of glutamate 
transmission by selective mGlu2/3 receptor agonists produce anxiolytic but 
not antipsychotic effects. It should be noted that anxiety and related underlying 
psychological processes are innate mechanisms in response to threatening stimuli, 
while schizophrenia is attributable to longitudinal and complex interactions of 
genetic, developmental, social and environmental factors (Weinberger, 1995; 
Lipska and Weinberger, 2000). Thus, animal models of anxiety seem to be 
more robust with higher predictive validity than pharmacological models of 
schizophrenia. Although acute ketamine or other NMDA receptor antagonist in 
healthy subjects can produce acute schizophrenic symptoms, these compounds 
may also induce compensatory mechanisms which in turn interfere with 
effects of the antipsychotics. Following this line of reasoning administration 
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of antipsychotics to healthy subjects prior to induction of the symptoms might 
activate such processes that lead to facilitation of psychomimetic effects. As we 
have demonstrated, treatment with mGlu2/3 receptor agonists led to facilitation 
of ketamine-evoked PPI deficit suggesting synergistic interaction of the two 
drugs probably in the GABAergic system (see above). 
 On the other hand, (post)treatment with the mGlu2/3 receptor agonist 
restored stress effects on EPM performance probably by suppressing presynaptic 
glutamate release. Since both ketamine effects and stress are associated with an 
increased glutamate efflux, it is possible that co-administration or post-treatment 
with mGlu2/3 receptor agonists might be more efficient to reduce ketamine-
evoked symptoms.
 It will be also interesting to investigate the antipsychotic properties of 
mGlu2/3 receptor agonists following chronic ketamine exposure. In humans, 
chronic administration of ketamine produces persistent and broad-spectrum 
symptoms which are remarkably similar to schizophrenia (Jentsch and Roth, 
1999). In rats repeated ketamine administration led to disrupted sensorimotor 
gating, impaired social interaction and enhanced response to MK801 (another 
non-competitive NMDA antagonist) challenge (Becker et al., 2003). Moreover, 
remarkable neurochemical  (increased dopamine D
2
 receptor binding in the 
hippocampus, decreased glutamate binding in the frontal cortex, changes in 
dopamine and serotonin transporter systems) and cellular changes (reduction of 
parvalbumin- immunoreactive hippocampal interneurons) were found following 
chronic ketamine exposure (Becker et al.,  2003; Keilhoff et al., 2004), which, in 
part, resembled those observed in postmortem brains of schizophrenia patients. 
These data support the idea that repeated administration of subanesthetic doses of 




Schizophrenia remains a disabling illness characterized in most patients 
by residual symptoms and recurrent relapse despite recent advances in 
pharmacological treatment. In addition to dopamine (D
2
) antagonism, the more 
recent “second-generation” agents share serotonin (5-HT
2
) receptor antagonism 
but differ from each other in possessing diverse patterns of activity at other 
receptors (Zhang and Bymaster, 1999). Among the newer antipsychotics, only 
clozapine has a clearly demonstrated enhanced efficacy in patients refractory 
to D
2
 antagonists, although roughly half of the patients still fail to respond to 
clozapine (Hellewell, 1999). 
The downstream effects of lamotrigine, a broad spectrum anticonvulsant, 
on neuronal function include inhibition of glutamate release. The clinical data 
currently demonstrated the add-on efficacy of lamotrigine in combination with 
antipsychotic drugs (Large et al., 2005). For instance, lamotrigine combined 
with clozapine is more effective in the treatment of positive and general 
psychopathological symptoms than clozapine alone among patients with 
treatment-resistant schizophrenia (Tiihonen et al., 2003). Thus, clinical data with 
lamotrigine support the use of drugs that reduce glutamate release as adjunctive 
treatments for patients with schizophrenia. Our results described in chapter 4, 
together with other reports (Lorrain et al., 2003a; Moghaddam and Adams, 
1998) showed that mGlu2/3 receptors agonists could prevent some aspects of 
NMDA hypofunction model of schizophrenia in rats (i.e. hyperlocomotion and 
working memory deficits) which may be associated with a reduced glutamate 
release. Based on these observations it seems to be plausible that administration 




Although the preclinical data, including our results (chapter 5), collectively 
indicate anxiolytic properties of mGlu2/3 receptor agonists, clinical evidences 
are not consistent. LY354740 was reported to restore fear-potentiated startle 
during shock anticipation (Grillon et al., 2003) and to reduce CO
2
-induced panic 
anxiety (Schoepp et al., 2003), but it failed to show improvement in patients with 
panic disorder following 9 weeks of treatment (Bergink and Westenberg, 2005). 
Similarly, LY544344, the peptidyl prodrug of LY354740, was ineffective in 
restoring choleocystokinin tetrapeptide (CCK-4) induced panic/anxiety (Kellner 
et al., 2005). Because of these conflicting clinical results, testing a more effective 
glutamatergic compounds in clinical trials is warranted. Here we showed that the 
LY379268 was more effective in restoring stress effects on EPM performance 
than LY354740 to the extent that LY379268 was active in both males and 
females. Thus, the more potent and high affinity LY379268 seems to be a possible 
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 Besides its essential function in energy metabolism, glutamate is the major 
excitatory neurotransmitter in the mammalian central nervous system. Therefore 
glutamate is involved in nearly all aspects of brain function including cognition, 
memory and learning. Consequently, abnormal changes in glutamatergic 
neurotransmission, in particular excessive glutamate release, can lead to a 
neuronal dysfunction resulting in a variety of neurological and psychiatric 
disorders including anxiety and schizophrenia. Therefore, there has been a great 
deal of interest in developing therapeutic strategies that can influence the function 
of glutamate receptors.
Before the discovery of metabotropic glutamate (mGlu1-8) receptors, it 
was thought that glutamate exerts its physiological action through receptors 
that act directly as ion channels. These ionotropic receptors (iGlu: NMDA, 
AMPA and kainate) are expressed by nearly all subtypes of neurons and mediate 
fast excitatory neurotransmission throughout the whole brain. Thus, direct 
pharmacological manipulation of this group of receptors may produce a global 
disruption in brain function and produce profound side effects ranging from 
disruption of movement to impairment of attention and memory.
Unlike iGlu receptors, the mGlu receptors modulates neuronal activity in a 
manner similar to neuromodulators such as dopamine and serotonin, which have 
been effective targets of psychoactive drugs for treatment of most psychiatric 
disorders. In addition, the distribution and function of these receptors is highly 
diverse and heterogeneous. As a consequence, mGlu receptor ligands might 
exemplify Ehrlich’s pharmacological ‘silver bullet’ that can modify glutamate 
neurotransmission in a functionally selective manner.
In the last decade, the members of group II metabotropic glutamate receptors 
(mGlu2/3) have emerged as potential therapeutic targets. Activation of the 
mGlu2/3 receptors provide a negative feedback mechanism to prevent excessive 
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presynaptic glutamate release in limbic regions that have been implicated in 
pathology of psychiatric disorders. Converging preclinical and recent clinical 
evidences supported the notion that administration of selective mGlu2/3 
receptor agonists, LY354740 and LY379268, represent a novel treatment for 
schizophrenia and anxiety/stress. Because of some recent conflicting results, 
the experiments described in this thesis were designed to further evaluate the 
proposed antipsychotic and anxiolytic properties of these compounds. 
SCHIZOPHRENIA
The dopaminergic hypothesis cannot totally explain the neuropathology of 
schizophrenia and this has led to the search for other errors in neurotransmission 
and the development of associated models. The psychotomimetic effects of 
noncompetitive NMDA receptor antagonists such as PCP and ketamine in 
healthy humans and their ability to exacerbate several psychotic symptoms in 
schizophrenic patients have prompted a view of schizophrenia as being related 
to a hypofunctional state of glutamatergic neurotransmission. Attempts to mimic 
these effects in animals have led to the recognition of parallels with behavioural 
and cellular abnormalities associated with schizophrenia. 
Chapter 2  describes this NMDA receptor hypofunction model of 
schizophrenia. Upon single subanasthetic dose of ketamine, the animals exhibit 
hyperlocomotion, working memory deficits and disruption in sensorimotor 
gating (PPI). As measured by c-fos expression, these behavioural abnormalities 
are associated with increased neuronal activity throughout the brain including 
prefrontal cortex, hippocampus, amygdala, nucleus accumbens and hypothalamus. 
Previous in vivo microdialysis studies demonstrated that such an increased 
neuronal activity following administration of NMDA receptor antagonists 
is linked to increased glutamate release.  Thus suppression of this increased 
glutamate efflux may restore the behavioural deficits evoked by ketamine and 
other NMDA receptor antagonists.
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 In fact, acute administration of mGlu2/3 receptor agonists has been 
demonstrated to prevent hyperlocomotion but not prepulse inhibition (PPI) 
deficits. Schizophrenia patients are deficient in the normal inhibition of the startle 
reflex that occurs when the startle stimulus is preceded by a weak prestimulus. 
The PPI paradigm is thought to be a measure of the deficient sensorimotor 
gating that underlies sensory flooding and cognitive fragmentation in these 
patients. Since PPI deficits are one of the key symptoms of schizophrenia 
resulting in information overflow and thought disorder, the lack of effect of 
acute pretreatment with LY354740 cast a doubt on the proposed antipsychotic 
properties of mGlu2/3 receptor agonists. Thus, first we investigated the effects 
of subchronic pretreatment with LY354740 on ketamine-induced PPI deficits as 
well as hyperlocomotion and c-fos expression. As described in chapter 3, this 
approach also failed to restore the ketamine effects on PPI, rather LY354740 
appeared to exaggerate the PPI deficit. Furthermore, LY354740 was ineffective 
to prevent ketamine-evoked hyperlocomotion and c-fos induction.    
Interestingly, both LY354740 and ketamine reduced the c-fos expression in 
the dentate gyrus (DG). This effect of LY354740 and ketamine might contribute 
to the potentiation of the PPI deficits when the two compounds were applied 
together: the hippocampus plays an important role in mediation of the PPI 
disruptive actions of NMDA antagonists and DG is the main hippocampal input 
with a high mGlu2/3 receptor density. Although speculative, it can be argued that 
pretreatment with LY354740 suppressed glutamate neurotransmission in DG via 
activation of presynaptic mGlu2/3 receptors, while ketamine further reduced it 
by blockade of postsynaptic NMDA receptors. Such a synergistic reduction in 
glutamate neurotransmission might lead to profound PPI deficits. 
As described in chapter 4, acute administration of the more potent mGlu2/3 
receptor agonist LY379268 also failed to restore PPI deficits evoked by ketamine. 
In fact, LY379268 enhanced the ketamine effects on PPI similarly to LY354740. 
However, LY379268 was able to prevent hyperlocomotion.  
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Since we observed synergistic interaction effect on c-fos expression between 
LY354740 and ketamine only in the DG, in chapter 4 we measured the ex vivo 
levels of glutamate and monoamines (dopamine, serotonin and noradrenaline) 
only in the DG following LY379268 and ketamine treatment. We demonstrated 
here that ketamine reduced the tissue level of glutamate and dopamine and 
the serotonin turnover. Pretreatment with LY379268 could only prevent the 
ketamine effect on glutamate without altering the basal glutamate concentration. 
This is in line with in vivo microdialysis studies which have demonstrated that 
activation of group II mGlu receptors by LY379268 or LY354740 has no effect 
on basal glutamate levels in the PFC or nucleus accumbens, even though these 
drugs can suppress NMDA antagonist-evoked glutamate (but not dopamine) 
release which was accompanied with blockade of PCP-evoked hyperlocomotion. 
Accordingly, the present data showed that LY379268 prevents the effects of 
ketamine on locomotion and glutamate transmission in the DG, but not on PPI 
and monoamine levels. Therefore, it is conceivable that blockade of ketamine and 
other NMDA antagonist-induced changes in glutamate neurotransmission can 
reverse hyperlocomotion, but that it is neither sufficient nor capable in restoring 
PPI deficits. This latter symptom may rather be linked to changes in monoamine 
transmission.  Previous reports do support such a relationship, as multireceptor-




antagonists) like clozapine, 
chlorpromazine, and ziprasidone appeared to be effective in reversing NMDA 
antagonist-induced PPI deficits. This may help to explain the ineffectiveness of 
the highly selective mGlu2/3 receptor agonist LY354740 in the present study: 
the drug did not effectively counter all the wide-ranging neuropharmacological 




In general, anxiety- and stress related disorders are thought of as a collection of 
illnesses that have in common excessive or inappropriate brain excitability within 
crucial brain region circuits, which leads to the expression of the symptoms. As 
glutamate is the main excitatory neurotransmitter in the mammalian brain, it is 
logical that the new approaches for treatment of anxiety/stress disorders could 
include drugs that modulate glutamatergic functions. 
While recent reports strongly suggest a role for mGlu2/3 receptors in the 
modulation of anxiety and stress-related disorders, all these studies focused on 
male experimental objects ignoring gender differences in anxiety/stress-related 
behaviour and in response to psychoactive drugs. Therefore chapter 5 designed 
to evaluate the anxiolytic properties of LY354740 and LY379268 in both gender. 
To the end, control and acutely stressed rats (2 days of inescapable footshock [IS] 
prior to test) were subjected to elevated plus maze test (EPM). 
Although none of the compounds showed anxiolytic effects under normal 
conditions, treatment with LY379268 could restore IS effects on EPM performance 
in both sexes. LY354740, however, was effective only in stressed females, but 
not in stressed males. Since the more potent structural analogue LY379268 was 
able to prevent IS-induced changes in males, the lack of LY354740 effect might 
be attributable to the dosage (3mg/kg) which is indeed lower than other studies 
used (10-20 mg/kg). This might also imply that males and females have different 
pharmacokinetic profiles for these drugs.
 The well established anxiolytic effects of mGlu2/3 receptor agonists have 
been associated with suppressed hippocampal neurotransmission. Furthermore, 
the hippocampus is particularly sensitive to stress in a gender dependent manner. 
Studies investigating neurogenesis of the DG have reported that stress reduces 
hippocampal plasticity in males with either no effect or stimulatory effects 
seen in females. Thus, we measured the expression of cAMP response-element 
binding protein (CREB) and its phosporylated form (pCREB) as a plasticity 
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marker by using western blot analysis to characterize stress and treatment effect 
on plasticity in the DG of male and female rats. 
Similar to the reversal effects of LY379268 on behaviour, treatment with this 
compound, but not with LY354740, could normalize the CREB level in stressed 
males without altering pCREB. In stressed females, however, all three compounds 
increased pCREB expression but there were no changes in CREB. These findings 
may indicate that mGlu2/3 receptor agonists have a gender dependent effect 
regarding regulation of CREB function: in males normalization of CREB 
level while in females increased activation of CREB appears to be involved in 
anxiolytic action of these compounds. However, the signaling pathway by which 
the mGlu2/3 receptors influence CREB function remains to be explored.
 
CONCLUSION
Altogether, our results do not support the proposed antipsychotic properties 
of mGlu2/3 receptor agonists, LY354740 and LY379268. None of the compound 
was able to restore sensorimotor gating deficits which are considered as the key 
symptoms of schizophrenia. However, future studies should examine the effects 
of these compounds on cognitive dysfunction related to schizophrenia.    
On the other hand, our results demonstrated the both LY354740 and 
LY379268 have anxiolytic properties in elevated plus maze test irrespectively 
of gender. These findings further suggest that modulation of mGlu2/3 receptor 
subtypes may indeed represent a new and safe approach for the treatment of 
anxiety. Since anxiety/stress is the major non-genomic factor that contributes to 
the expression or exacerbation of in schizophrenic symptoms, recurrence after 
a period of remission and treatment outcome, mGlu2/3 receptor agonists might 
be also applied as an additional treatment in combination with antipsychotics to 




Glutamaat heeft een essentiële functie in het energiemetabolisme, maar 
daarnaast is het de belangrijkste excitatoire (stimulerende) neurotransmitter in 
het centrale zenuwstelsel. Glutamaat is betrokken bij bijna alle aspecten van het 
functioneren van de hersenen, zoals cognitie, leren en geheugen. Abnormale 
veranderingen in dit systeem, met name overmatige glutamaat afgifte, kan dan 
ook leiden tot het niet meer goed functioneren van het brein wat resulteert in een 
scala aan neurologische en psychiatrische stoornissen, zoals angststoornissen en 
schizofrenie. Dit heeft geleid tot een grote belangstelling voor de ontwikkeling 
van farmacologische therapieën die de functie van glutamaat receptoren 
kunnen beïnvloeden.Voor de ontdekking van de metabotrope glutamaat (mGlu) 
receptoren werd gedacht dat glutamaat zijn werking uitoefende via receptoren die 
functioneren als ionkanalen. Deze ionotrope receptoren (iGlu: NMDA, AMPA en 
kainate receptoren) komen voor in de celmembraan van bijna alle neuronen en 
zorgen voor een snelle signaalgeleiding in het brein. Farmacologische manipulatie 
van ionotrope receptoren kan daarom het functioneren van grote delen van de 
hersenen verstoren waardoor bijwerkingen, variërend van bewegingstoornissen 
tot achteruitgang van concentratie en geheugen ontstaan.    
In tegenstelling tot de iGlu receptoren moduleren de mGlu receptoren de 
neuronale activiteit op een wijze die vergelijkbaar is met die van neurotransmitters 
zoals dopamine en serotonine. Deze laatst genoemde monoamines en in het 
bijzonder hun receptoren zijn ook de aangrijpingspunten voor psychoactieve 
stoffen die heden ten dage gebruikt worden bij de behandeling van veel 
psychiatrische stoornissen. Net als de monoamine receptoren is de verdeling 
en functie van de metabotrope glutamaatreceptoren divers en heterogeen. 
Dientengevolge, zouden mGlu receptor liganden de glutamaat neurotransmissie 
kunnen beïnvloeden op een functionele en selectieve manier en daarmee voldoen 
aan Ehrlichs farmacologische ‘zilveren kogel’ theorie.
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In het laatse decennium zijn de groep II metabotrope glutamaat receptoren 
(mGlu2/3) naar voren geschoven als potentiële therapeutische doelen. Activatie 
van deze mGlu2/3 receptoren voorkomt excessieve glutamaatafgifte door een 
negatief feedback mechanisme. Een verstoorde glutamaatafgifte is waarschijnlijk 
een onderdeel van de pathobiologie bij een scala van psychiatrische stoornissen. 
Preklinische en klinische data tonen dat toediening van selectieve mGlu2/3 
receptor agonisten (LY354740 en LY379268) een rol zouden kunnen gaan spelen 
bij de behandeling van schizofrenie en angst/stress stoornissen. Dit proefschrift 
beschrijft experimenten die zijn ontworpen om de mogelijke antipsychotische en 
anxiolytische eigenschappen van mGlu2/3 agonisten te onderzoeken. 
SCHIZOFRENIE
Ondanks jaren van onderzoek is er nog steeds veel onduidelijkheid over 
de neuropathologie van schizofrenie. De psychotomimetische effecten van 
de non-competitieve NMDA receptor antagonisten zoals PCP en ketamine in 
gezonde vrijwilligers alsmede de eigenschap van deze stoffen om psychotische 
symptomen te verergeren bij patiënten, was aanleiding voor de hypothese van 
hypofunctioneren van glutamaat neurotransmissie bij schizofrenie. Pogingen 
om deze effecten in dieren na te bootsen heeft verstoringen in beeld gebracht 
die parallellen tonen met gedrags- en cellulaire veranderingen die worden 
geassocieerd met schizofrenie. 
Hoofdstuk 2 beschrijft experimenten die zijn gebaseerd op het NMDA receptor 
hypofunctioneren model van schizofrenie. Eenmalige toediening van ketamine 
resulteerde in hyperlocomotie bij ratten, verstoringen van het werkgeheugen en 
‘sensorimotor gating’ (PPI). Met c-fos immunocytochemie hebben we aangetoond 
dat deze gedragsveranderingen geassocieerd zijn met een toegenomen neuronale 
activiteit in de prefrontale cortex, hippocampus, amygdala, nucleus accumbens en 
hypothalamus. In vivo microdialyse had al laten zien dat deze activiteitstoename 
is gerelateerd aan een toename van de glutamaat afgifte. Wij onderzochten of de 
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onderdrukking van de ketamine-geinduceerde glutamaat afgifte met de selectieve 
mGlu 2/3 agonist LY354740 de gedrags- en neurobiologische veranderingen zou 
kunnen normaliseren.
Acute toediening van mGlu2/3 receptor agonisten voorkomt ketamine-
geinduceerde hyperlocomotie maar niet de PPI afwijkingen. Verstoringen van 
de “sensorimotor gating” is een van de kernsymptomen van schizofrenie, en een 
teken van een informatie ‘overflow’ en ‘thought disorder’. Het ontbreken van een 
acuut effect van LY354740 op PPI verstoring draagt bij aan vergroting van de 
twijfel aan de potentiele antipsychotische eigenschappen van mGlu2/3 agonisten. 
Vervolgens hebben we, naast gedrags- en c-fos expressie-veranderingen, 
de effecten van subchronische behandeling met LY354740 op ketamine 
geïnduceerde PPI verstoringen onderzocht. Zoals beschreven in Hoofstuk 3, was 
ook deze benadering niet succesvol. Subchronische toediening van LY354740 
leek de PPI verstoringen eerder te versterken dan te voorkomen. Ook werden de 
door ketamine geïnduceerde hyperlocomotie en veranderingen in c-fos expressie 
niet genormaliseerd.
Een interessante observatie was dat zowel LY354740 als ketamine de c-fos 
expressie in de dentate gyrus (DG) van de hippocampus verlaagden. Dit effect 
zou kunnen bijdragen aan de waargenomen versterking van de PPI verstoringen 
wanneer de 2 stoffen simultaan werden toegediend. De DG heeft een hoge 
concentratie aan mGlu2/3 receptoren en is de belangrijkste input regio van 
de hippocampus die een belangrijke rol speelt bij ketamine-geinduceerde PPI 
verstoring. Onze hypothese voor het synergistische effect van ketamine en 
LY354740 is dat LY354740 de glutamaat neurotranmissie in de DG onderdrukt 
via activatie van de presynaptische mGlu2/3 receptoren en dat ketamine de 
glutamaatafgifte verder verlaagt door blokkering van postsynaptische NMDA 
receptoren. Ook de acute toediening van de meer potente mGlu2/3 receptor 
agonist LY379268 kon de PPI verstoringen niet herstellen (Hoofdstuk 4). 
Deze agonist (LY379268) versterkte zelfs de effecten van ketamine en was 
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daarmee vergelijkbaar met LY354740, maar in tegengstelling tot LY354740 
voorkwam deze meer potente agonist LY379268 wel de ketamine-geïnduceerde 
hyperlocomotie. Omdat c-fos expressie alleen in de DG effecten van behandeling 
toonde van LY354740 en ketamine, hebben we in een vervolgexperiment in de 
DG de ex-vivo niveaus van glutamaat en de monoamines dopamine, serotonine 
en noradrenaline gemeten na toediening van LY 379268 en ketamine. Ketamine 
reduceerde in de DG de niveaus van glutamaat en dopamine en de ‘turnover’ 
van serotonine . Voorbehandeling met LY379268 voorkwam de effecten die 
ketamine had op het glutamaat niveau, zonder de basale glutamaat concentratie 
te beïnvloeden. Dit komt overeen met in vivo microdialyse experimenten die 
hebben aangetoond dat activatie van groep II mGlu receptoren door LY379268 
en LY 354740 geen effect had op basale glutamaat niveaus in de PFC of nucleus 
accumbens.
Op basis van onze resultaten is de conclusie gerechtvaardigd dat de PPI 
verstoringen bij schizofrenie meer worden bepaald door veranderingen in het 
monoamine dan in het glutamaat systeem. Voorgaande studies ondersteunen 





antagonisten) zoals clozapine, chlorprozamine en ziprasidone effectief lijken 
in het voorkomen van NMDA antagonist geïnduceerde PPI verstoringen. Dit 
kan een verklaring zijn voor het gebrek aan effectiviteit van de selectieve 
mGlu2/3 receptor agonist LY354740; dit farmacon kon niet de uiteenlopende 
neurofarmacologische effecten van ketamine tegengaan. 
ANGST
Angst en stressgerelateerde aandoeningen worden gezien als een verzameling 
van stoornissen die excessieve of ongepaste activiteit laten zien van een aantal 
limbische hersengebieden, wat aanleiding is voor de symptomen. Aangezien 
glutamaat de meest prominente excitatoire neurotransmitter is in het brein, spreekt 
het voor zich dat nieuwe ontwikkelingen op het gebied van de behandeling van 
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angst- en stressstoornissen zich ook richten op farmaca die de glutamaterge 
systeem beïnvloeden. 
Verschillende recente onderzoeken wijzen in de richting van een rol voor 
mGlu2/3 receptoren in de modulatie van angst en stress. Echter, deze studies zijn 
allemaal uitgevoerd bij mannelijke proefdieren, waarbij men negeert dat angst- en 
stressgerelateerde stoornissen veel vaker voorkomen bij vrouwen. Hoofdstuk 5 
beschrijft een experiment waarin de anxiolytische eigenschappen van LY354740 
en LY379268 bij zowel mannetjes- als vrouwtjesratten worden geëvalueerd. De 
ratten werden gedurende 2 dagen blootgesteld aan footshock stress, waarna ze 
een ‘elevated plusmaze test’(EPM) ondergingen (een gedragstest voor angst). 
Onder controle condities had geen van de agonisten een anxiolytisch effect, 
echter behandeling met LY379268 was in staat om de stressgeïnduceerde angst te 
voorkomen bij mannetjes en vrouwtjes. 
Het minder potente LY354740 was effectief bij gestreste vrouwtjes maar 
niet bij de mannetjes. Hieraan zou een geslachtsgerelateerd verschil in 
farmacokinetiek ten grondslag kunnen liggen omdat wij deze minder potente 
agonist lager doseerden dan in voorgaande studies (3 mg/kg vs. 10-20 mg/kg). 
De anxiolytische effecten van mGlu2/3 agonisten worden geassocieerd met een 
onderdrukking van neurotransmissie in de  hippocampus. Ook is de hippocampus 
op een geslachtsspecifieke manier gevoelig voor de effecten van stress. 
Neurogenese (een vorm van plasticiteit van het centrale zenuwstelsel) in de 
hippocampus toont na stress een afname bij mannetjes, terwijl bij vrouwtjes geen 
veranderingen of een toename worden waargenomen. In Hoofdstuk 5 beschrijven 
wij veranderingen in de expressie van cAMP response-element binding protein 
(CREB) en z’n geactiveerde gefosforyleerde vorm (pCREB) in de DG om de 
effecten van behandeling met mGlu2/3 agonisten en stress te onderzoeken bij 
mannetjes- en vrouwtjesratten. Deze CREB en pCREB zijn betrokken bij de 
cellulaire processen die belangrijk zijn voor het in stand houden van plasticiteit 
van de hersenen. Vergelijkbaar met de effecten op gedrag voorkwam LY379268, 
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maar niet LY354740, de effecten van stress op de expressie van CREB bij 
mannetjes, echter zonder dat de niveaus van pCREB veranderden. Bij gestreste 
vrouwtjes resulteerden alle behandelingen in toename van de pCREB niveaus, 
waarbij de totale CREB expressie niet was veranderd. Deze bevindingen lijken 
aan te tonen dat mGlu2/3 receptor agonisten een geslachtsspecifiek effect 
hebben op de regulatie van CREB; bij mannetjes werd het niveau van de CREB 
expressie genormaliseerd terwijl bij vrouwtjes een toegenomen activiteit van 
CREB (gemeten aan het pCREB niveau) aan de anxiolytische effecten van de 
mGlu2/3 agonisten ten grondslag lijkt te liggen. Hoe mGlu2/3 receptor agonisten 
het functioneren van de CREB signaaltransductie beïnvloeden is voor alsnog 
onduidelijk.
CONCLUSIE
Samengevat, onze resultaten onderschrijven niet de veronderstelling dat 
de mGlu2/3 receptor agonisten LY354740 en LY379268 antipsychotische 
eigenschappen zouden hebben. Geen van beide stoffen was in staat om 
sensorimotor gating verstoringen te normaliseren, terwijl dit toch wordt gezien 
als een van de kernsymptomen van schizofrenie. Dit laat niet onverlet dat 
toekomstige studies wel de effecten van deze stoffen zouden moeten onderzoeken 
op de cognitieve aspecten die eveneens verstoord zijn bij schizofrenie. Onze 
resultaten toonden dat de beide mGlu2/3 agonisten (LY354740 en LY379268) 
anxiolytische eigenschappen hebben en dat dit effect onafhankelijk was van het 
geslacht. Deze bevindingen suggereren dat modulatie van mGlu2/3 receptor 
subtypes een nieuwe en veilige benadering zou kunnen zijn voor de behandelijk 
van angst. Omdat stress een belangrijke, niet genetische factor is die bijdraagt 
aan het ontstaan van, of het verergeren van symptomen schizofrenie, en omdat 
deze psychiatrische stoornis ook wordt gekenmerkt door angst zouden mGlu2/3 
receptor agonisten, in combinatie met antipsychotica, een additionele behandeling 
kunnen zijn die bijdraagt aan verbetering van de effectiviteit.  
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